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1. Introduction 
1.1 Podophyllotoxin 
Podophyllotoxin has been used as folk medicine for centuries. The source 
of podophyllotoxin is the resin of Podophyllum rhizome, especially the 
resin extracted from Podophyllum peltatum (May apple or American 
mandrake) and Podophyllum haxandrum (syn. P. emodi). Both of them are 
the plant species currently used for the extraction of podophyllotoxin. 
Podophyllum peltatum L. (Fig. 1) is indigenous to the eastern part of the 
United States of America and Canada. Podophyllum haxandrum is found in 
the higher parts of the Himalayan Mountains and is also referred to as the 
Indian Podophyllum. North American Indians and inhabitants of the 
Himalayas used the extracts of the plants Podophyllum peltatum and 
Podophyllum hexandrum as an emetic, cathartic, mortal poison, antidote 
for snake venom, anthelminthic, cholagogue and expectorant. In 1942, 
podophyllotoxin was reported in pharmacopoeia as a topical application 
for genital warts. Podophyllotoxin is most notable among the tubulin 
binding ligands and acts as an inhibitor of microtubules. Its action takes 
place by inhibiting the polymerisation of tubulin and stopping cell division 
at the beginning of the metaphase. Podophyllotoxin is an important lead 
compound for synthetic cytotoxic agents with lower toxicity but higher 
efficacy1.  
 
Figure 1. Podophyllum peltatum L. 
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1.2 Etoposide 
Etoposide, a potent antineoplastic drug, was one of several 
podophyllotoxin derivatives that were first synthesised in the 1960s and 
were then introduced into cancer clinical trials in the early 1970s. It is a 
semisynthetic glucosidic derivative of podophyllotoxin, which is a natural 
product compound extracted from Podophyllum peltatum and 
Podophyllum hexandrum belonging to the family of Berberidaceae. Its 
chemical structure is shown in Fig. 2. Etoposide provides superior 
pharmacological profiles and broader therapeutic potential compared to 
podophyllotoxin. The chemical formula of etoposide is C
29
H
32
O
13
 with a 
molecular weight of 588.56 g/mol. The melting point of etoposide is 236 - 
251 °C. Etoposide is highly soluble in methanol and chloroform, slightly 
soluble in ethanol but only sparingly soluble in water. Thus, drug 
formulations for intravenous administration contain organic co-solvents 
such as benzyl alcohol, polyethylene glycol, and ethanol1-6.  
 
Synonyms of etoposide are  
- Demethylepipodophyllotoxin-ethylidene-glucopyranoside 
- EPEG 
- EPE 
- Epipodophyllotoxin 
- 4α-Demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D-
glucopyranoside)  
- 4α-Demethylepipodophyllotoxin ethylidene-β-D-glucoside  
- (–)-Etoposide  
- trans-Etoposide  
- VP 16 
- VP 16-123 
- VP 16-213 
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Figure 2. Chemical structures of podophyllotoxin (A) and etoposide (B) 
1.2.1 Mechanism of action  
Deoxyribonucleic acid (DNA) topoisomerases are nuclear enzymes 
inducing transient breaks in the DNA allowing DNA strands or double 
helices to pass through each other. DNA topoisomerases are classified into 
two groups: topoisomerase I enzymes that induce single stranded cuts into 
DNA and topoisomerase II enzymes that cut and pass double stranded 
DNA7. The major mechanism of action of etoposide is mainly explained by 
the interaction with topoisomerase II. By binding to topoisomerase II, 
etoposide stabilises the cleavable complexes which results in double 
strand and single strand breaks in the DNA. Unlike podophyllotoxin, 
etoposide does not arrest cell division at the mitotic phase by binding to 
microtubules, but induces a premitotic block prevalent in the late S or 
early G
2
 period both in vitro and in vivo. Cells that are duplicating their 
DNA for the mitosis are very sensitive for this mechanism. The inability of 
etoposide to inhibit microtubule assembly is due to the glucoside moiety 
which sterically blocks the interaction with tubulin. Breaks in the DNA are 
caused by either an interaction with DNA topoisomerase II or the formation 
O
O
O
OH
OCH3H3CO
H OH
O
O
O
OH
OCH3H3CO
O H
O
O
O
H3C
O
HO
HO
A B
O
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of free radicals. Until now, it is still not clear how stabilisation of the DNA 
topoisomerase II-etoposide complex ultimately leads to cell death and 
etoposide may also have other mechanisms of cytotoxicity2,4,8-10.  
1.2.2 Pharmacodynamics 
Etoposide has demonstrated cytotoxic activity against a variety of different 
tumours including adenocarcinoma lung cell lines, anaplastic 
bronchogenic carcinoma cell lines, human T cell lymphoma cell lines, 
leukaemic cell lines, lymphoid (T1) cell lines, human diploid embryo lung 
fibroblast cell lines, choriocarcinoma cell lines, cell lines derived from 
acute nonlymphoblastic leukaemia, cell lines derived from B- and T-
lymphomas, cell lines derived from Hodgkin’s disease, small cell lung 
carcinoma cell lines, haematopoietic cell lines, medulloblastoma cell lines 
and neuroblastoma cell lines2,11,12. Etoposide demonstrates a remarkable 
schedule-dependence as shown in in vitro studies and suggested by 
clinical trials. The cytotoxicity of etoposide is both concentration- and 
time-dependent. In in vitro studies, leukaemia cells were incubated with 
etoposide at different concentrations (25 nM – 400 nM) and various 
exposure times (2 – 8 days) but the total drug exposure was kept constant. 
At the same total drug exposure, significantly greater cytotoxicity was 
achieved in schedules involving longer exposure times compared to those 
with short exposure times13. T-cell lymphoma (MOLT) and human 
anaplastic bronchogenic carcinoma cells (9812) were incubated with 
etoposide at a concentration range from 0.01 – 10.0 µg/mL. Each 
etoposide concentration was exposed to the cells with exposure durations 
of 1, 3, 18 and 30 h. Etoposide cytotoxicity increased with etoposide dose 
and duration of exposure14.  
The schedule-dependence of etoposide activity was also confirmed in 
clinical studies15. Clinical response was compared in small cell lung cancer 
patients who received etoposide as 500 mg/m2 continuous infusion over 
24 h and patients who received 100 mg/m2 etoposide as two hourly 
infusion for five consecutive days. The response rate of etoposide 
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500 mg/m2 continuous infusion over 24 h (10 %) was significantly lower 
than that after etoposide 100 mg/m2 two hourly infusion for five 
consecutive days (89 %)16.  
The schedule-dependence of efficacy and toxicity of etoposide was also 
evaluated after an oral administration in small cell lung cancer patients. 
Etoposide was given orally in 78 patients in three different dosage 
regimens: 50 mg twice daily for 14 days every three weeks, 50 mg once 
daily for 21 days every four weeks and etoposide 50 mg twice daily for ten 
days every three weeks. Partial responses were observed in 76 %, 52 % and 
70 % of the patients, respectively. This study demonstrated that a twice-
daily regimen is preferable17.  
So far, the concentration- and schedule-dependent cytotoxicity of 
etoposide has been reported from both in vitro studies and in vivo 
studies13,14,16-23. However, there is sparse information about the 
concentration- and schedule-dependent effect of etoposide on CNS tumour 
cell lines especially medulloblastoma and PNET. Furthermore, there is still 
a lack of information on etoposide cytotoxicity from in vitro studies which 
simulate drug exposure conditions as those encountered in the patient. 
The time of exposure to etoposide from most in vitro studies was up to 
24 h, whereas in the clinical situation etoposide is often administered 
intravenously over 3 - 5 consecutive days or orally over 14 - 21 consecutive 
days16,17,23.  
1.2.3 Clinical use 
Etoposide is a highly effective and widely used agent for both the curative 
and palliative treatment of many neoplastic diseases including germ cell 
tumours, Kaposi’s sarcoma associated with AIDS, Hodgkin’s disease, Non-
Hodgkin’s lymphoma, mycosis fungoides, acute myeloblastic leukaemia, 
neuroblastoma, Ewing’s sarcoma, paediatric rhabdomyosarcoma, ovarian 
carcinoma, small cell lung cancers, non-small cell lung cancers, gastric 
cancer and hepatoma. Etoposide is also used in the preparatory 
chemotherapeutic regimens given prior to bone marrow transplantation in 
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patients with advanced haematological malignancies. Major adverse effects 
of etoposide include hair loss, nausea, anorexia, diarrhoea, leucopenia and 
thrombocytopenia. Etoposide is known to cause fetal damage and birth 
defects2,5,6,8,24-26. 
1.3 Childhood brain tumours and therapy 
 Brain tumours are the most common solid tumour types in paediatric 
patients. They are the leading cause of cancer-related morbidity and 
mortality secondary to childhood malignancies. Childhood brain tumours 
differ from primary central nervous system (CNS) tumours occurring in 
adults with regard to their relative incidences, histological features, sites 
of origin and responsiveness to therapy. The types of paediatric brain 
tumours are classified according to location and histological 
appearance27,28 (Tab. 1). The causes of paediatric brain tumours remain 
unknown. The most common forms of childhood brain tumours are 
primitive neuroectodermal tumours (PNET) including medulloblastomas. 
Symptoms of paediatric brain tumours comprise of repeated, frequent 
headaches and nausea or vomiting29. Currently the principle management 
strategies of brain tumours consist of surgical therapy, radiotherapy and 
chemotherapy. The type of tumours, the age of the patient and the 
likelihood of treatment-induced nervous system damage must be 
considered in order to find the optimal treatment strategy for each 
individual patient. Basically both surgical therapy and radiation improve 
the chance of cure and prolong survival time30. However, there are some 
complications to the CNS after surgical therapy or radiation. After 
treatment with surgery, patients have a higher risk of permanent cranial-
nerve and long tract deficits, transient pseudobulba symptoms and mutism. 
Moreover after cranial or craniospinal radiation significant adverse 
neuroendocrine and neurologic deficits, as well as impairment of 
intellectual function were observed especially in children younger than 
three years of age29,31.  
Chemotherapy is one approach which was introduced in order to reduce 
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the degree of neurocognitive sequelae resulting from surgical therapy or 
radiotherapy. Chemotherapy can be used to reduce the tumour size in 
order to decrease the risk associated with surgical therapy29,31. Duffner et al. 
demonstrated that postoperative chemotherapy can delay radiotherapy in 
children younger than three years32. Overall survival rates were comparable 
between patients who received full-dose radiation therapy alone and 
patients who received reduced-dose radiotherapy plus chemotherapy31,33-35. 
Moreover, chemotherapy has also shown to increase survival rates in 
childhood medulloblastoma and PNET patients who received chemotherapy 
with radiotherapy compared with those children receiving radiotherapy 
alone36-38. These studies indicated that the dose of radiation therapy can be 
reduced when chemotherapy is administered resulting in a lower incidence 
of neurocognitive sequelae which is the major adverse effect after 
radiation. Therefore, chemotherapy has gained an increasing role in 
paediatric brain tumour therapy. 
 
Table 1. Classification of paediatric brain tumours modified according to 
location and histological appearance (derived from Pollack28). 
Location and type of tumour 
Percentage of all brain 
tumours 
Infratentorial 
Primitive neuroectodermal tumour  
    (Medulloblastoma) 
Low-grade astrocytoma, cerebellar 
Ependymoma 
Malignant glioma, brain stem 
Low-grade astrocytoma, brain stem 
Other 
Total 
 
20 - 25 
 
12 - 18 
4 - 8 
3 - 9 
3 - 6 
2 - 5 
45 - 60 
Supratentorial hemispheric 
Low grade glioma 
High grade glioma 
 
8 - 20 
6 - 12 
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Ependymoma 
Mixed glioma 
Ganglioglioma 
Oligododendroglioma 
Choroid-plexus tumour 
Primitive neuroectodermal tumour 
Meningioma 
Other 
Total 
2 - 5 
1 - 5 
1 - 5 
1 - 2 
1 - 2 
1 - 2 
0.5 - 2 
1 - 3 
25 - 40 
Supratentorial midline 
Suprasellar 
  Craniopharyngioma 
  Low-grade glioma, chiasmatic 
hypothalamic 
  Germ-cell tumour 
  Pituitary adenoma 
Pineal region 
  Low-grade glioma 
  Germ-cell tumour 
  Pineal parenchymal tumour 
Total 
 
 
6 - 9 
4 - 8 
1 - 2 
0.5 - 2.5 
 
1 - 2 
0.5 - 2 
0.5 - 2 
15 - 20 
  
1.4 Intraventricular administration of chemo-
therapy  
Chemotherapy can prolong survival of brain tumour patients, especially in 
patients with anaplastic gliomas, oligodendrogliomas, medulloblastoma, 
PNET, germ cell tumours and primary CNS lymphoma (PCNSL). At present, 
chemotherapy is used as primary therapy or an additional therapy 
following surgery and/or radiation therapy39. However, the major problem 
in treating CNS tumours is the limited passage of cytotoxic drugs across 
the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (B-CSFB) 
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and the cerebrospinal fluid-brain barrier (CSF-BB)40. In an attempt to 
circumvent systemic toxicity and obtain higher CSF concentrations of 
etoposide the intraventricular (ivc) administration was introduced. Using 
this route of administration high drug concentrations are obtained in the 
CSF after relatively low doses. The drug can be infused intraventricularly by 
using an Ommaya reservoir (OMR). An OMR is a dome-shaped reservoir. It 
measures 3.4 cm in diameter and is placed subcutaneously in the scalp 
and connected to the ventricles within the brain via an outlet catheter as 
shown in Fig. 3. The drug is injected into the implanted reservoir and 
delivered to the ventricles by manual compression. Most common 
complications of reservoir implantation are infections, failures in 
placement, reservoir or catheter obstruction or dysfunction41,42.  
 
Figure 3. Drug delivery via an Ommaya reservoir (OMR)43. 
 
Direct ivc administration of chemotherapy through an indwelling 
subcutaneously implanted OMR has an advantage over intralumbar 
administration because the drug is delivered in the same direction as the 
CSF bulk flow. Thus, the ivc injection results in a wider distribution of the 
drug throughout the CSF compartment. Moreover, there is remarkably less 
patient discomfort since the ivc administration is not painful in contrast to 
the lumbar puncture (LP). Furthermore, the most meaningful advantage of 
the ivc route is the possibility of administration of repeated low doses of a 
drug over a relatively short period of time. This is also called the 
Introduction 
 
10
`concentration times time´ (C x T) approach. By using this strategy a 
prolonged duration of CSF exposure to cytotoxic drug concentrations is 
obtained, excessively high peak concentrations are avoided and the total 
drug dose is reduced44,45.  
Until now, effective treatment of CNS tumours has still been limited by the 
paucity of cytotoxic agents that can be administrated by the ivc route. At 
present, methotrexate, cytarabine and thiotepa are widely used for intra-
CSF therapy. Methotrexate and cytarabine are antimetabolites and highly 
effective in treating CNS leukaemia. However, methotrexate can cause 
leucoencephalopathy in patients who received cranial radiation46,47 and 
cytarabine alone shows weak activity in malignant brain tumours47. 
Thiotepa diffuses out of the CSF rapidly and furthermore, after intrathecal 
administration of thiotepa the active metabolite TEPA is not formed48,49. To 
enhance the success of brain tumour therapy with ivc administration, many 
other chemotherapeutic agents such as etoposide, mafosfamide, 
fluorouracil, topotecan, diaziquone, temozolomide, sustained release 
cytarabine, monoclonal antiganglioside antibody have been studied in 
clinical trials49-60. 
1.4.1 Preclinical study 
Eight beagle dogs received [3H] etoposide at 2 mg/kg by intrathecal or 
intravenous administration. Plasma, urine, bile, cerebrospinal fluid, brain 
tissue and tissue of major organs were collected to analyse the etoposide 
concentrations. The intrathecal group exhibited higher etoposide 
concentrations in CSF and brain tissues compared with the intravenous 
group. No acute neurologic toxicity and no histopathologic changes were 
reported. The intrathecal administration was well tolerated at the dosage 
used61,62.  
1.4.2 Clinical studies  
The ability of etoposide to pass across the BBB and the B-CSFB into the CSF 
is extremely poor, even after high-dose systemic intravenous or oral 
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administration. In 16 patients, the peak concentration of etoposide in CSF 
ranged only from 0.04 - 0.11 µg/mL after oral administration (50 - 
150 mg/day) or intravenous infusion over one hour (55 - 65 mg/m2)63. 
After intravenous infusion over two hours (300 mg/m2) or oral 
administration for 21 days (50 and 25 mg/m2/day) in 20 patients, the 
median etoposide concentrations in CSF were 0.103 µg/mL, 6.47 x         
10-3 µg/mL and 4.12 x 10-3 µg/mL, respectively64. Even when high doses 
(400 - 800 mg/m2/day) over two or three hours were given intravenously, 
the concentrations of etoposide in the CSF ranged from 0.1 - 1.4 µg/mL or 
1.8 ± 1.7 % of simultaneously measured plasma concentrations65. Posmus 
et al. reported that after extremely high intravenous doses (900 – 
2500 mg/m2) over one hour every 12 h for three consecutive days, the CSF 
concentrations of etoposide were only up to 0.54 µg/mL66. The poor 
distribution of etoposide into the CSF despite its lipophilic properties is 
thought to be due to the high binding affinity of the drug to proteins in 
the blood circulation67,68.  
In order to circumvent this problem, the ivc administration of etoposide 
was attempted. In 1992, van der Gaast et al. published the administration 
of intraventricular etoposide in two patients. An etoposide dose of 0.5 mg 
was given ivc once daily for five consecutive days. Three weeks later 
0.5 mg were administered every 12 h for five consecutive days. The 
etoposide concentrations in the CSF obtained at 2 – 2.30 h after ivc 
administration ranged from 3.6 – 5.2 µg/mL and at 22 – 24 h from 0.2 – 
0.6 µg/mL69. No treatment-related adverse effects in two patients were 
reported in these patients. Cytological examination showed that the CSF 
was free of leukaemic cells following the treatment69.  
In 2001, our group reported that intraventricularly administered etoposide 
0.5 mg/day for five consecutive days repeated every 2 - 5 weeks over a 
period of 0 up to 11 months was well tolerated in 14 patients. The CSF 
peak concentrations exceeded more than 100-fold those obtained after 
intravenous infusion. The pharmacokinetic parameters were estimated by 
using a two-compartment model. The AUC (area under the concentration-
time curve), CL (clearance), V
ss
 (volume of distribution at steady-state) and 
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 (terminal elimination half-life) of the treatment group without systemic 
etoposide were 21.9 ± 10.3 µg x h/mL, 0.56 ± 0.48 mL/min, 0.20 ± 0.18 L 
and 7.65 ± 1.24 h, respectively. Interindividual variability of the 
pharmacokinetic parameters was three times higher than the 
intraindividual variability70. Toxicity of intraventricularly administered 
etoposide was evaluated in the same patients (59 courses). Mild transient 
headache was found in 2 of 59 courses. Meningitis was found in 2 of 59 
courses. 5 of 14 patients showed an improvement in neurological 
symptoms or pain reduction. 6 patients of 14 patients showed no changes. 
3 patients had progressive symptoms70. Slavc et al. reported that etoposide 
did not cause any discomfort in 11 patients following etoposide ivc 
administration of 0.5 mg daily for five consecutive days, repeated every 3 - 
6 weeks for a total of 122 courses51. However, the effectiveness of 
intraventricularly administered etoposide alone cannot be determined from 
these studies because the patients received systemic chemotherapy 
simultaneously and also irradiation.  
Aims  
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2. Aims of this investigation 
  
Up to now, there is still a lack of pharmacokinetic data of etoposide after 
ivc administration. To optimise the dosage of intraventricularly 
administered etoposide, the pharmacokinetic disposition in the CSF was 
investigated after three different dosage regimens; 0.25 mg/12 h, 
0.5 mg/24 h and 1 mg/24 h. Additionally, CSF samples were drawn 
simultaneously from the OMR and by lumbar puncture (LP) in order to 
elucidate the distribution of etoposide within the CSF compartment. 
Moreover, the effect of the dosage regimen on the antiproliferative effect 
of etoposide in medulloblastoma cells was studied by using the colony 
forming assay. The in vitro dilution model was used to simulate 
concentration-time profiles similar to those encountered in vivo.  
 
The following objectives were defined: 
- To estimate the pharmacokinetic parameters of etoposide in the CSF 
after ivc administration of three different dosage regimens 
(0.25 mg/12 h, 0.50 mg/24 h and 1 mg/24 h). 
- To evaluate the distribution of etoposide after ivc administration 
through an OMR. 
- To generate a CSF pharmacokinetic model for simulation of other 
regimens. 
- To evaluate the effect of etoposide concentration and area under the 
concentration-time curve (AUC) on the growth of medulloblastoma 
cells. 
- To evaluate the antiproliferative effect of two different 
concentration-time profiles similar to those encountered in vivo 
(0.25 mg/12 h and 0.50 mg/24 h). 
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3. Materials and Methods 
3.1 Pharmacokinetic study 
3.1.1 Materials  
Chemicals 
Methanol HPLC grade Merck, Darmstadt, Germany  
J.T. Baker, Deventer, 
Netherlands 
Sodium chloride, pure  Merck, Darmstadt, Germany 
Disodiumhydrogen phosphate Merck, Darmstadt, Germany 
Phosphoric acid 85 % (V/V) Riedel-de-Häen, Seelze, 
Germany 
Purified water PurelabTM plus USF, Ransbach-Baumbach, 
Germany 
Vepesid-JTM Bristol-Myers Squibb, Munich, 
Germany 
  
Consumption materials 
Sample microvial (100 µL and 250 µL) CS-Chromatographie Service 
Ltd., Germany 
Sample vials  Labomedic, Bonn, Germany 
Polytetrafluoroethylene gasket for  
sample vial 
CS-Chromatographie Service 
Ltd., Germany 
Metal springs Labomedic, Bonn, Germany 
Polypropylene tubes (15 mL) Greiner Bio-one, 
Frickenhausen, Germany 
Reaction vial Safe-LockTM 0.5 mL,1.5 mL Eppendorf Hamburg, 
Germany 
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Pipette Tips 200 µL, 1000 µL Greiner Bio-one, 
Frickenhausen, Germany 
Membrane filter NL17 (0.45 µm, Ø 47 mm) Schleicher & Schuell, Dassel, 
Germany 
Sterile membrane filter 0.22 µM, cellulose 
acetate 
Merck, Darmstadt, Germany 
Graphite filter ESA Inc. Chelmsford, USA 
ParafilmTM Peckiney Plastic Packing, 
Neenah, USA 
  
3.1.2 Equipment 
System GoldTM HPLC Instrumentation  
 
Beckman Coulter, Fullerton, 
USA 
CoulochemTM II Detector system ESA Inc., Chelmsford, USA 
HPLC column, NucleosilTM 100-5 C18  Macherey-Nagel, Düren, 
Germany 
Heraeus HERAsafeTM, laminar airflow HSP12 Kendro Laboratory Products, 
Germany 
Single pan precision balance 770 Kern, Albstadt, Germany 
pH-Meter inoLabTM 2P WTW, Weilheim, Germany 
Sonicator SonorexTM super RK 103 H Bandelin, Berlin, Germany 
Vortex mixture L46 GLW, Würzburg, Germany 
Vacuum membrane pump ME 4 C Vacuubrand, Wertheim, 
Germany 
FisherbrandTM pipette (10 - 100 µL) Fisher Scientific, Schwerte, 
Germany 
VoluTMMate pipette  
(20 - 200 µL/100 - 1000 µL) 
Mettler Toledo, Giessen, 
Germany 
PurelabTM plus water purification system USF, Ransbach-Baumbach, 
Germany 
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3.1.3 HPLC analysis for the determination of etoposide in 
CSF 
HPLC system components 
Pump HPLC pump 125 Beckman Coulter, 
Fullerton, USA 
Sample operation system Autosampler 507 with 
100 µL sample loop 
Beckman Coulter, 
Fullerton, USA 
Column NucleosilTM 100-5 RP-
C18, 5 µm,  
150 x 4.6 mm 
Macherey-Nagel, 
Germany 
Electrochemical detector  ESA CoulochemTM II 
with Guard cell 5020 
Analytical cell 5010 
ESA Inc., Chelmsford, 
USA 
Interface Analogue Interface 
Module 406 
Beckman Coulter, 
Fullerton, USA 
Integration software  GoldTM 32 Karat, 
version 3.0 
Beckman Coulter, 
Fullerton, USA 
 
Chromatographic conditions 
Chromatographic separations of etoposide in CSF were performed on a 
NucleosilTM 100-5 C-18 (150 x 4.6 mm, 5 µm) analytical column under 
isocratic condition. The mobile phase consisted of methanol/ 0.01 M 
disodiumhydrogen phosphate (Na
2
HPO
4
) in a ratio of 52:48 (V/V) and was 
adjusted with 85 % (V/V) phosphoric acid (H
3
PO
4
) to pH 6.0. The mobile 
phase was degassed by using helium prior to use. Flow rate was set at 
0.7 mL/min. Etoposide was quantified by electrochemical detection using a 
dual electrode at the potentials E
1
 = 100 mV and E
2
 = 500 mV. The guard 
cell was set at 550 mV. 
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Buffers and solutions 
0.9 % sodium chloride: 4.5 g sodium chloride were transferred to a 
500 mL volumetric flask and dissolved with purified water. The solution 
was filtered by using a 0.22 µm membrane filter. 0.9 % NaCl solution was 
used as matrix for calibration instead of CSF. 
0.01 M disodiumhydrogen phosphate (pH 6.0): 1.4196 g 
disodiumhydrogen phosphate
 
were dissolved in purified water and 
adjusted to a volume of 1000 mL. The solution was mixed with methanol 
for use as mobile phase and adjusted with 85 % (V/V) phosphoric acid to 
pH 6.0. The mobile phase was filtered by using a 0.45 µm membrane filter. 
0.02 M disodiumhydrogen phosphate (pH 5.3): 0.2839 g 
disodiumhydrogen phosphate were added to purified water and the 
volume was adjusted to 100 mL. The pH was adjusted to 5.3 by using 85 % 
(V/V) phosphoric acid. The solution was filtered by using a 0.22 µm 
membrane filter. The solution was used to mix with CSF samples in order 
to prevent isomerisation of etoposide during analysis. 
Suitability of 0.9 % NaCl as matrix for calibration 
As it is difficult to obtain enough blank CSF for calibration, the suitability 
of 0.9 % NaCl was investigated by Henke71. Recovery of spiked etoposide in 
blank CSF was compared to 0.9 % NaCl at etoposide concentrations of 
0.2 µg/mL, 1 µg/mL and 5 µg/mL and ranged from 96.5 - 106.6 %. The 
results showed that saline solution spiked with etoposide provided similar 
peak heights as blank CSF spiked with etoposide. Therefore, saline 
solution was used as matrix for the preparation of calibrators and quality 
control samples. 
Preparation of calibrator solutions 
A 5 mL vial of VepesidTM containing 100 mg etoposide in a mixture of 
150 mg benzyl alcohol, 3250 mg macrogol 300, 1210 mg absolute 
ethanol, citric acid and polysorbate 80 was used for preparing etoposide 
stock solutions. The stock solutions were prepared by dilution with 0.9 % 
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NaCl and stored at a temperature ≤ 20 ºC until use. The concentrations of 
etoposide stock solutions were 100, 10 and 1 µg/mL. Etoposide 
concentrations in CSF samples were determined by using five different 
calibration curves at five different sensitivity range sets (50 nA, 2 µA, 5 µA, 
10 µA and 20 µA) of the detector. Calibrator solutions were prepared by 
dilution of the stock solutions with 0.9 % NaCl. Each calibration curve 
contained at least six concentrations of etoposide (s. Tab. 2). 
Sample preparation 
CSF samples of patients were kept at temperature -80 ºC until analysis. The 
samples were left at room temperature to defrost. Because only low 
protein concentrations are found in the CSF, protein precipitation is not 
required. 80 µL of CSF were mixed with 40 µL of 0.02 M Na
2
HPO
4
 (pH = 5.3) 
in order to prevent isomerisation of etoposide during sample processing 
and analysis. A 40 µL aliquot of the prepared sample was injected onto the 
HPLC system. The temperature of the autosampler tray was set at 18 ºC. 
3.1.4 Assay validation  
Method validation is the process which shows that an analytical method is 
acceptable for its intended purpose. In general, a bioanalytical method 
must be validated with regard to specificity, linearity, accuracy, precision, 
recovery, limit of detection, and limit of quantification. For the 
determination of etoposide in CSF, a method of Reif et al.72,73 was modified. 
Hence the HPLC assay in this work was only partially validated regarding 
selectivity, linearity, accuracy and precision according to international 
recommendations74,75.  
Selectivity  
Selectivity is used to confirm that the procedure is measuring only the 
compound of interest and that the quantification is not affected by the 
sample matrix components. The selectivity of the HPLC method was 
assessed by comparison of chromatograms of buffer and CSF samples 
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containing etoposide with chromatograms obtained after injection CSF of 
the respective blank matrix. 
Linearity and calibration 
Linearity means that assay response increases proportionally with 
increasing concentration. The calibration curve should consist of six to 
eight calibrator samples. In this study, at least six calibrators were used to 
check linearity. Calibrator samples were prepared independently, to make 
it easier to discover an error in any of the samples compared to 
preparation by serial dilution. The range of etoposide concentrations for 
the calibration curves at different sensitivity ranges are shown in Tab. 2. 
The calibration curves were prepared daily for each concentration range. 
By using the Software “Method Validation in Analytics” (MVA), Version 2.0 
(Novia GmbH, Saabrücken, Germany), the peak heights were plotted 
against nominal (theoretical value) etoposide concentrations to construct 
the calibration curve using 1/X weighting. If the measured response has a 
linear relationship with the concentration, it can be described with the 
linear equation as shown below:  
 
+bi=aXiY  (eq. 1) 
Where: 
Y
i
 = Measured response 
a = Slope  
X
i
 = Concentration of the analyte 
b = Intercept  
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Table 2.  Concentration ranges of etoposide for each sensitivity  
Sensitivity of detector Concentration range of calibration curve [µg/mL] 
20 µA 30, 40, 50, 60, 80, 100 
10 µA 15, 20, 25, 30, 32.5, 35 
5 µA 6.25, 7.5, 8.75, 10, 15, 17.5 
2 µA 2, 2.5, 3.125, 4.375, 5, 6.875 
50 nA 0.05, 0.075, 0.125, 0.15, 0.175, 0.20 
  
Accuracy 
The accuracy of an analytical method quantifies how close the 
concentrations obtained by the method are to the nominal concentrations 
of the analyte. Accuracy is determined by replicate analysis of samples 
containing known amounts of analyte. Accuracy can be divided into two 
categories: within-day accuracy and between-day accuracy. For within-day 
accuracy, control samples of each calibration curve were measured six 
times on the same day. For between-day accuracy, control samples of each 
calibration curve were measured once per day on six different days. Ten 
control samples of etoposide were analysed six times each (two 
concentrations for each sensitivity) as shown in Tab. 3. The accuracy was 
reported as percentage relative error (RE) as shown in equation 2. The 
percentage RE value should be within ± 15 % of the nominal value except at 
the lower limit of quantification, where it should not deviate by more than 
± 20 %.  
 
[ ] 100⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
nom
nomcal
C
CC%RE       (eq. 2) 
Where:  
RE [%] = Percentage relative error 
C
cal
 = Measured concentration 
C
nom
 = Nominal concentration 
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Table 3. Control samples of each calibration curve for the determination of 
accuracy and precision (n = 6) 
Sensitivity range 
of the 
EC detector 
Conc. range of calibration curve 
[µg/mL] 
Conc. of control 
samples 
[µg/mL] 
40.0 
20 µA 30.0 - 100.0 
80.0 
20.0 
10 µA 15.0 - 35.0 
32.5 
7.5 
5 µA 6.25 - 17.5 
10.0 
2.5 
2 µA 2.0 - 6.875 
5.0 
0.10 
50 nA 0.05 - 0.2 
0.18 
 
Precision 
The precision of an analytical procedure expresses the degree of scatter in 
a series of individual measurements when the analytical procedure is 
applied repeatedly to multiple aliquots of the same sample. The precision 
of an analytical method is usually expressed as percentage coefficient of 
variation (% CV) as shown in equation 3. The % CV should not exceed 15 % 
except for the lower limit of quantification, where it should not exceed 
20 %. The precision is subdivided into within-day precision and between-
day precision. For within-day precision, control samples of each calibration 
curve were measured six times on the same day. For between-day 
precision, control samples of each calibration curve were measured once 
per day on six different days. Ten control samples of etoposide were 
analysed six times each (two concentrations for each calibration curve, s. 
Tab. 3.)  
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Where: 
% CV = Percentage coefficient of variation 
X = Mean value from n measurements 
X
i
 = Measured individual values 
n = Number of measurements 
   
3.1.5 Clinical study design and patient characteristics 
The study was designed as an open prospective clinical and 
pharmacological trial in an individual curing framework76. 
Patient with an age between three months to 30 years and a refractory or 
relapsed metastatic malignant brain tumour, i.e. spinal, ventricular and/or 
parenchymatous metastases and/or meningeosis, were eligible. 
The following patients were excluded: 
- Patients who had severe or life-threatening neurological symptoms 
and/or therapy-resistant seizures (WHO scale 4)77.  
- Patients who had severe non-haematological insufficiencies (e.g., 
renal, cardiac, pulmonary or hepatic) (WHO scale 4) and life-
threatening infections (WHO scale 3 or 4)77. 
- Patients who had hydrocephalus occlusus or malresorptivus which 
disturb CSF circulation or CSF resorption and need 
ventriculosystemic shunt. 
- Patients who had a proximal CSF flow obstruction. 
The patient characteristics are summarised in Tab. 4 and more detailed in 
Appendix A1.  
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Table 4. Patient characteristics 
Gender 
      Male 
      Female 
 
12 
10 
Age (years) 
      Median 
      Range 
 
11.20 
3.50 – 32.40 
Weight (kg) 
      Median 
      Range 
 
34.80 
10.30 – 77.00 
Height (cm) 
      Median 
      Range 
 
141.00 
88.90 – 179.50 
BSA (m2) 
      Median 
      Range 
 
1.18 
0.50 – 1.95 
Diagnosis 
Non-CNS tumour with brain metastases  
Acute lymphoblastic leukaemia 
CNS tumour 
Medulloblastoma / PNET 
Ependymoma 
Pineoblastoma 
Intraspinal tumour 
   Plexuscarcinoma 
 
 
1 
 
16 
2 
1 
1 
1 
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The study protocol was approved by the local ethics committee of the 
University of Bonn. Before entering the study, all patients and their parents 
were informed of the investigational nature of the study and the potential 
risks of these regimens as well as of the poor prognosis of relapsed 
metastatic brain tumours. Their consent to treatment was obtained.  
The treatment of the patients followed the HIT-REZ-97-Study-Protocol 
which comprised surgical excision, irradiation and local/systemic therapy 
of anticancer agents62. Antiemetics and analgesics were used as supportive 
medication. 
3.1.6 Drug formulation, administration and dosage 
There are three market brands of etoposide: VepesidTM (Bristol-Myers 
Squibb, Germany), ETO-GRYTM (GRY-Pharma-Ltd., Germany) and ETO-CSTM 
(Pharmacia Ltd., Germany) which were used in this study. Benzyl alcohol 
which is a component in VepesidTM was reported as neurotoxic      
substance78-80. Therefore, since 4 April 2002, VepesidTM was not used in the 
study anymore. From that day onwards, the patients obtained etoposide in 
the form of ETO-GRYTM and ETO-CSTM which do not contain benzyl alcohol 
as solvent. A 5 mL vial of ETO-GRYTM and ETO-CSTM contains 100 mg 
etoposide and macrogol 300, citric acid, polysorbate 80 and ethanol 100 % 
as solvent. Etoposide was administered to all patients by ivc administration 
via an indwelling Ommaya or Rickham reservoir3,81,82. The commercial 
solution was diluted in the following steps to yield the final concentration 
of 0.2 mg/mL (1:100, V/V):  
- In the first step 0.5 mL of the commercial solution (20 mg/mL) were 
diluted with preservative-free, pyrogen-free saline (0.9 % NaCl) 
9.5 mL to obtain etoposide 1 mg/mL.  
- This solution was further diluted with preservative-free, pyrogen-free 
saline (0.9 % NaCl) to 0.2 mg/mL as shown below: 
Etoposide 0.25 mg = 0.25 mL etoposide 1 mg/mL  
+ 1 mL 0.9 % NaCl 
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Etoposide 0.50 mg = 0.50 mL etoposide 1 mg/mL 
+ 2 mL 0.9 % NaCl  
Etoposide 1.0 mg = 1.00 mL etoposide 1 mg/mL 
+ 4 mL 0.9 % NaCl 
 
The reservoir was punctured under sterile conditions with a 27-gauge 
butterfly needle. 2 mL CSF were discarded or removed for culturing. 5-
10 mL CSF were removed for diagnosis (chemical, pathology and 
pharmacokinetics) and 2 mL were removed for flushing after drug 
administration. Following the administration the reservoir was pumped five 
times to ensure adequate mixing throughout the ventricular CSF. 
Etoposide was given to patients in three different dosage regimens; 
0.25 mg/12 h, 0.50 mg/24 h and 1.0 mg/24 h. Each dosage regimen was 
given for five consecutive days which was one cycle and repeated every 
two to five weeks.  
3.1.7 Sample collection 
Samples collected for measuring etoposide concentrations were obtained 
from cycles without any interference from etoposide systemic 
administration. CSF samples following etoposide 0.25 mg/12 h were 
collected at 0 and 0.25, 1, 2, 4 and 12 h on day 1 and at 0.25 and 12 h on 
day 2 to day 5. The CSF samples following etoposide 0.5 mg/24 h and 
1 mg/24 h were collected at 0 and 0.25, 1, 2, 4, 8, 12 and 24 h on day 1 
and at 0.25 and 24 h on day 2 to day 5. Four hours after administration 
one CSF sample was drawn by lumbar puncture in order to investigate the 
distribution of etoposide within the CSF.  
The CSF samples were collected in heparinised tubes, rapidly centrifuged 
at 10000 rpm for two minutes and the supernatant was frozen at -80 ºC 
until analysis.  
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3.1.8  Non-compartmental pharmacokinetic data analysis 
Etoposide pharmacokinetic parameters in CSF such as maximum 
concentration (C
max
), minimum concentration (C
min
) and time to reach 
maximum concentration (t
max
) were estimated without the assumption of a 
specific model. They were directly taken from the observed concentration-
time curve83,84. 
3.1.9 Compartmental pharmacokinetic data analysis  
The pharmacokinetic parameters such as area under the curve (AUC), 
volume of distribution at steady-state (V
ss
), clearance (CL), elimination half-
life of the first phase (t
1/2λ1) and terminal elimination half-life (t1/2z) were 
estimated by using compartmental analysis assuming a two-compartment 
model. Due to the limited number of samples, Bayesian curve fitting was 
applied by means of the software SipharWinTM (release 1.14, Simed, Créteil, 
France). 
Compartmental model of etoposide in CSF  
Etoposide pharmacokinetic parameters in CSF were estimated by using a 
two-compartment model with first-order elimination from the central 
compartment as shown in Fig. 4.  
  
Figure 4. Schematic presentation of a two-compartment model  
Where:  
 = Direction of mass flow 
K
12
 = Rate constant for the transfer from 
the central compartment to the 
peripheral compartment 
K
10
 
K
21
 
Central 
compartment 
Peripheral 
compartment 
Elimination 
K
12
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K
21
 = Rate constant for the transfer from 
the peripheral compartment to the 
central compartment 
K
10
 = Elimination rate constant  
 
 
The CSF etoposide concentration-time profile after ivc administration was 
described by a two exponential equation as shown below. 
 
tλ
z
tλ
t 
zeCeCC ⋅⋅ ⋅+⋅= 11  (eq.4) 
Where: 
C
t
 = Concentration at time t  
C
1
 = Intercept after extrapolation of the first 
phase back to the y-axis 
C
z 
= Intercept after extrapolation of the 
terminal phase back to the y-axis 
λ
z
 = Terminal elimination rate constant  
λ
1
 = Elimination rate constant of the first phase  
t = Time  
 
Model parameters 
Volume of distribution of the central compartment (V
c
), ratio of 
concentrations in SipharWinTM (r
c
), elimination rate constant of the first 
phase (λ
1
) and terminal elimination rate constant (λ
z
) were used as model 
parameters. V
c
 and r
c
 were calculated as shown in equation 5 and 6, 
respectively. 
 
z 
c CC
D  V += 1  (eq.5) 
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z
c CC
Cr += 1
1
 (eq.6) 
 
Estimation of population parameters  
The population values for the model parameters were estimated from data 
of seven patients (three patients following 1 mg/24 h and four patients 
following 0.5 mg/24 h) undergoing full sampling. In the first step, initial 
parameters were estimated using curve peeling. These initial parameters 
were needed for the nonlinear regression procedure. In the next step, the 
selected model (two-compartment model) was fitted to the observed data 
applying a numerical algorithm based on the Powell method and 
minimising the weighted sum of squared deviations (WSS): 
 
2
1
ˆ )C(CWWSS ii
n
i
i −=∑
=
 (eq.7) 
Where:   
W
i 
= Weighting factor at time i 
n = Number of measured concentrations  
C
i 
= Observed concentration at time i 
iCˆ  = Estimated concentration at time i 
 
 
The individual model parameters obtained from the best fitted curve are 
shown in Tab. 10 in the result section. Since the model parameters were 
obtained from seven patients after administration of two different dosage 
regimens, it was tested, whether the model parameters differed between 
the two groups by using the Mann-Whitney U test. The results of the test 
are shown in Tab. 11 in the result section. No differences were found 
between the model parameters of the two groups. Therefore, mean values 
and standard deviations were calculated from the individual model 
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parameters of the seven patients. These parameters were used as 
population parameters as shown in Tab. 12 in the result section. 
Estimation of individual parameters by Bayesian curve fitting 
The two-compartment model was fitted to the experimental data applying 
a numerical algorithm based on the Powell method including the mean 
values and variances of the population parameters. Weighted least-squares 
or extended least-squares methods were used to minimise the Bayesian 
objective function (OBJ
Bayes.
) as equation 8. 
 
∑∑
==
−+−⋅=
k
j j
jj
ii
n
i
iBayes. σ
)P(P
)C(CW OBJ
1
2
2
2
1
ˆ
ˆ  (eq.8) 
 
Where: 
OBJ
Bayes.
 = Bayesian objective function 
W
i 
= Weighting factor at time i 
n = Number of observations 
k = Number of model parameters 
C
i
 = Measured CSF concentration at time i 
iCˆ  = Estimated CSF concentration at time i  
P
j 
= Population mean value of the jth model 
parameter  
jPˆ  = Estimated value for the j
th model 
parameter  
σ
j 
= Population standard deviation for the jth 
model parameter  
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Calculation of pharmacokinetic parameters 
The following pharmacokinetic parameters were calculated: 
 
Area under the curve ( ∞−0AUC ) 
z
z
λ
C
λ
CAUC +=∞−
1
1
0   (eq.9) 
 
Area under the first moment curve ( ∞−0AUMC ) 
22
1
1
0
z
z
λ
C
λ
CAUMC +=∞−  (eq.10) 
 
Clearance (CL) 
∞−
=
0AUC
DCL
 (eq.11) 
 
Volume of distribution at steady-state (V
ss
) 
 
2
0
0
)(AUC
AUMCDVSS
∞−
∞−⋅=   (eq.12) 
 
Terminal elimination half-life (t
1/2z
) 
 
 
z
z/ λ
t 2ln21 =  (eq.13) 
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Elimination half-life of the first phase (t
1/2λ1) 
 
1
21
2ln
1 λ
t λ/ =  (eq.14) 
 
Simulation of concentration-time profiles 
Etoposide concentration-time profiles after multiple bolus injection were 
simulated using the following equation85: 
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Where: 
τ = Dosing interval [h] 
n = Number of administration 
 
3.1.10 Statistical analysis 
Statistical calculations were performed with SPSSTM software package, 
version 12.0 (SPSS Inc., Chicago, USA). 
Descriptive statistics 
The descriptive statistics such as median (X
~
), mean ( X ), standard devia-
tion (SD), range, coefficient of variation (CV) and box plots were used to 
describe the basic features of the data in this study. 
 
Median (X
~
) is the score found at the exact middle of the ordered data set. 
Half of the scores are above the median and half are below. When there is 
an odd number of numbers, the median is the middle number. When there 
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is an even number of numbers, the median is the mean of the two middle 
numbers. 
 
Mean ( X ) is the average value of the data set: 
n
X
  X
n
i
i∑
== 1  (eq.16) 
where:  
X
i 
= Individual value 
n = Number of observations 
 
 
Range is the difference between the largest and the smallest observed 
value of the data set.  
 
Standard deviation (SD) is a measure of the spread or dispersion of a set 
of data:  
( )
1
1
2
−
−
=
∑
=
n
XX
 SD 
n
i
i 
 (eq.17) 
 
Coefficient of variation is used to measure the spread of a set of data as 
in relation to its mean. It is often showed as a percentage and calculated 
as the ratio of the sample standard deviation to the sample mean: 
100⋅=
X
SD CV[%]  (eq.18) 
 
Box plots  
The data were graphically presented by means of box plots. The box plot 
as shown in Fig. 5 provides a visual summary of median, upper and lower 
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quartile as well as maximum and minimum values of the data set. The box 
itself contains the middle 50 % of the data. The box stretches from the 
lower hinge (Q1) which was defined as the 25th percentile to the upper 
hinge (Q3) which was defined as the 75th percentile. The difference of two 
quartiles (Q3-Q1) is known as the inter-quartile range. The median is 
shown as a line across the box. The vertical lines extend from the top or 
bottom of the box to the maximum and minimum value, respectively. 
Outliers are marked with a circle (O), when the values are above (Q3) or 
below (Q1) 1.5 times of the inter-quartile range as shown in equations 19 
and 20. The extreme values are marked with an asterisk (*), when the 
values are above (Q3) or below (Q1) 3 times of the inter-quartile range as 
shown in equations 21 and 22. 
 
 
 
Figure 5. Box plot  
 
 
* 
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O ≤ Q1 – 1.5 x (Q3-Q1) (eq.19) 
O ≥ Q3 + 1.5 x (Q3-Q1) (eq.20) 
* ≤ Q1 – 3 x (Q3-Q1) (eq.21) 
* ≥ Q3 + 3 x (Q3-Q1) (eq.22) 
 
Inferential statistics 
Inferential statistics was used to make inferences about a population on 
the basis of the collected data. The null hypothesis is stated as no 
difference of the data between two or more populations. On the other 
hand, the alternative hypothesis is stated as the opposite to the null 
hypothesis. In this study, the null hypothesis was rejected when the level 
of significance (p value) was  ≤ 0.05. 
The following statistical tests were used: 
- The Shapiro-Wilk-test was used to assess whether data were 
normally distributed. 
- The Mann-Whitney U test was used to assess whether the model 
parameters obtained from the patients undergoing full sampling 
following etoposide 1 mg/24 h and those obtained from the patients 
following etoposide 0.5 mg/24 h were different. 
- The Kruskal-Wallis test was used to assess whether the 
pharmacokinetic parameters from three different dosage regimens 
were different.  
- The paired t-test was used to compare the etoposide concentrations 
which were obtained from an Ommaya reservoir and those after 
lumbar puncture.  
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3.2 In vitro study 
3.2.1 Materials  
Chemicals 
Methanol HPLC grade Merck, Darmstadt, Germany 
and J.T. Baker, Deventer 
Netherlands 
Methanol analytical grade J.T. Baker, Deventer 
Netherlands 
Disodiumhydrogen phosphate Merck, Darmstadt, Germany  
Sodium chloride Merck, Darmstadt, Germany  
Potassiumdihydrogen phosphate Merck, Darmstadt, Germany  
Potassium chloride Merck, Darmstadt, Germany  
Phosphoric acid 85 % (V/V) Riedel-de-Häen, Seelze, 
Germany 
Purified water (PurelabTM plus) USF, Ransbach-Baumbach, 
Germany 
Vepesid-JTM Bristol-Myers Squibb, 
Munich, Germany 
Acetonitrile HPLC Grade LCG Promochem GmbH, 
Wesel, Germany 
Dulbecco’s Modified Eagle Medium  
(DMEMTM) with GlutaMaxTM 
Invitrogen Gibco, Karlsruhe, 
Germany 
Fetal calf serum  Sigma-Aldrich Chemie, 
Steinheim, Germany 
L-Glutamine (200 mM) Sigma-Aldrich Chemie, 
Steinheim, Germany 
Penicillin-streptomycin solution 
Conc. penicillin: 10000 I.E./mL 
Conc. streptomycin: 10 mg/mL 
Sigma-Aldrich Chemie, 
Steinheim, Germany 
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Dimethylsulfoxide (DMSO) Promochem GmbH, Wesel, 
Germany 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] 
Sigma-Aldrich Chemie, 
Steinheim, Germany 
Isopropanol 100 % Merck, Darmstadt, Germany 
HCl 0.1 M Grüssing, Filsum, Germany 
CasyTMton, isotonic solution Schärfe System, Reutlingen, 
Germany 
Giemsa colour Sigma-Aldrich Chemie, 
Steinheim, Germany 
Crystal violet  Sigma-Aldrich Chemie, 
Steinheim, Germany 
Glycerine Merck, Darmstadt, Germany 
Ethanol 96 - 100 % analytical grade Merck, Darmstadt, Germany 
 
Consumption Materials 
Sample microvial (100 µL and 250 µL) CS-Chromatographie 
Service Ltd., Germany 
Sample vials Labomedic, Bonn, Germany 
Polytetrafluoroethylene gasket for  
sample vial 
CS-Chromatographie 
Service Ltd., Germany 
Metal springs Labomedic, Bonn, Germany 
Polypropylene tubes (15 mL, 50 mL) Greiner Bio-one, 
Frickenhausen, Germany 
Reaction vial safe-lockTM 0.5 mL, 1.5 mL Eppendorf Hamburg, 
Germany 
Pipette tips 200 µL, 1000 µL Greiner Bio-one, 
Frickenhausen, Germany 
Membrane filter NL17 (0.45 µm, Ø 47 mm) Schleicher & Schuell Dassel, 
Germany 
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Sterile membrane filter 0.22 µM, cellulose 
acetate 
Merck, Darmstadt, Germany 
ParafilmTM Peckiney Plastic Packing, 
Neenah USA 
Cell culture T-flask 25 cm2, 75 cm2, 175 cm2 Greiner Bio-one, 
Frickenhausen, Germany 
6-wells Petri-dish Greiner Bio-one, 
Frickenhausen, Germany 
96-wells Petri-dish Greiner Bio-one, 
Frickenhausen, Germany 
Disposable Plastic Pipette 10 mL Braun, Melsungen, Germany 
Glass Pipette 10 mL, 20 mL Brand, Wertheim, Germany 
Pasteur Pipette Brand, Wertheim, Germany 
Sterile glass bottle Schott Duran, Germany 
  
3.2.2 Equipment 
System GoldTM HPLC Instrumentation  
 
Beckman Coulter, Fullerton, 
USA 
HPLC column, NucleosilTM 100-5 C18  Macherey-Nagel, Düren, 
Germany 
Heraeus HERAsafeTM, laminar airflow HSP12 Kendro Laboratory 
Products, Germany 
Single pan precision balance 770 Kern, Albstadt, Germany 
pH-Meter inoLabTM 2P WTW, Weilheim, Germany 
Sonicator SonorexTM super RK 103 H Bandelin, Berlin, Germany 
Vortex mixture L46 GLW, Würzburg, Germany 
Vacuum membrane pump ME 4 C Vacuubrand, Wertheim, 
Germany 
FisherbrandTM pipette (10 - 100 µL) Fisher Scientific, Schwerte, 
Germany 
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VoluTMMate pipette  
(20 - 200 µL/100 - 1000 µL) 
Mettler Toledo, Giessen, 
Germany 
TransferpetteTM-12 multi-canal pipette  
20 - 200 µL 
Brand, Wertheim, Germany 
Aspirator pour pipette Accu-jetTM Brand, Wertheim, Germany 
Beckman MicrofugeTM Lite (centrifuge) Beckman Coulter, Munich, 
Germany 
Centrifuge AllegraTM 21R Beckman Coulter, Munich, 
Germany 
Speed VacTM SC 110 Savant Instruments INC. 
Holbrook, USA 
PolarstarTM –Galaxy photometer   BMG-Lab-Technologies, 
Offenburg, Germany 
CasyTM1 Cell counter Schärfe System, Reutlingen, 
Germany 
Vacuum pump type model DOA-U155-BN Benton Harbor Mich, USA 
Cell culture incubator WTC Binder WTC Labortechnik, 
Truttlingen, Germany 
Water bath Büchi, Switzerland 
Invert microscope AxiovertTM 25 Carl Zeiss AG, Oberkochen, 
Germany 
  
3.2.3 Cell medium, buffer and solutions 
Cell medium: 500 mL of cell culture medium (DMEMTM with GlutaMaxTM) 
were supplemented with 50 mL fetal bovine serum (FBS), 7.5 mL L-
Glutamine (200 mM) and 5 mL penicillin/streptomycin solution (penicillin: 
10000 I.E./mL/ streptomycin: 10 mg/mL) and kept in the refrigerator. The 
medium was warmed in the water bath at 37 ºC about 15 min before use. 
PBS (Phosphate buffer saline solution): 8 g sodium chloride, 1.4 g 
disodiumhydrogen phosphate, 0.2 g of potassiumdihydrogen phosphate 
and 0.2 g potassium chloride were transferred to a 1000 mL volumetric 
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flask and dissolved with purified water. The pH was adjusted to 7.4 with 
1 M sodium hydroxide. The solution was sterilized before use. 
0.01 M disodiumhydrogen phosphate (pH 6.0): 1.4196 g 
disodiumhydrogen phosphate
 
were dissolved in purified water and 
adjusted to a volume of 1000 mL. The solution was mixed with methanol 
for use as mobile phase and adjusted with 85 % (V/V) phosphoric acid to 
pH 6.0. The mobile phase was filtered by using a 0.45 µm membrane filter. 
0.05 M disodiumhydrogen phosphate (pH 5.3): 0.7098 g 
disodiumhydrogen phosphate were added into purified water and the 
volume was adjusted to 100 mL. The pH was adjusted to 5.3 by using 
85 % (V/V) phosphoric acid. The solution was filtered by using a 0.22 µm 
membrane filter. The solution was used to mix with samples in order to 
prevent isomerisation of etoposide during analysis. 
Giemsa stain solution: 0.75 mg of Giemsa powder were mixed with 
50 mL of glycerine and placed at 60 ºC for 2 h. 50 mL of methanol was 
added before use.  
Crystal violet stain solution: 0.20 g of crystal violet powder were mixed 
with 2 mL ethanol. The volume was adjusted to 100 mL with purified water. 
Stain solution for the colony forming assay: Stain solution was 
composed of Giemsa solution and crystal violet solution in a ratio 1:1 (V/V). 
MTT solution: 100 mg of MTT powder were added into purified water and 
the volume was adjusted to 20 mL. The solution was protected from light 
with aluminium foil. 
3.2.4 HPLC analysis for the determination of etoposide in 
cell culture medium 
Etoposide concentrations in cell culture medium were measured by HPLC 
with UV detection.  
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HPLC system components 
Pump HPLC pump 125 Beckman Coulter, 
Fullerton, USA 
Sample operation system Autosampler 507 with 
100 µL sample loop 
Beckman Coulter, 
Fullerton, USA 
Column NucleosilTM 100-5 RP-
C18, 5  µm, 
150  x  4.6  mm 
Macherey-Nagel, 
Germany 
Detector  GoldTM 168 UV detector   Beckman Coulter, 
Fullerton, USA 
Integration software  GoldTM 32 Karat, version 
3.0 
Beckman Coulter, 
Fullerton, USA 
 
Sample preparation and analysis 
100 µL of medium samples were mixed with 300 µL acetronitrile and 15 µL 
of 0.05 M disodiumhydrogen phosphate pH 5.3 and then centrifuged at 
10000 g for 10 minutes. 350 µL of the supernatant were evaporated to 
dryness and the residue was dissolved with 120 µL of the mobile phase 
which consisted of methanol and phosphate buffer pH 5.3 in a ratio 
52:48 (V/V). 50 µL of the respective mixture were injected onto the HPLC 
system. The flow rate was set at 0.7 mL/min and the UV detector at 
210 nm. 
Stability of etoposide in cell culture medium 
Etoposide stability in cell culture medium (Dulbecco’s Modified Eagle 
Medium (DMEMTM) with GlutaMaxTM) under incubation conditions was 
investigated. A solution of etoposide 10 µg/mL in culture medium (DMEMTM 
with GlutaMaxTM) was prepared and placed in the incubator for 72 h. 
Samples were collected at 0, 1, 2, 4, 8, 12, 24 and 48 and 72 h 
respectively, and analysed with HPLC. 
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3.2.5 Cell line 
The medulloblastoma cell line (D-425med) was obtained from Prof. Pietsch, 
Institute of Neuropathology, University of Bonn. The cells were 
cryopreserved with nitrogen gas in cell culture medium containing 10 % 
dimethylsulfoxide (DMSO) and kept under liquid nitrogen. The cells were 
thawed by using the water bath at 37 ºC and immediately propagated in 
the medium. The cells were then kept in an incubator under a humidified 
atmosphere of 5 % CO
2
 at 37 ºC. The cells were harvested in the 
exponential growth phase and detached from culture flasks by flushing 
with culture medium. All experiments were done by using cells of the 16th 
passage in order to avoid variations among different passages which could 
affect the results. 
3.2.6 MTT assay 
Principle 
The cytotoxic activity of etoposide was studied by using MTT assay. MTT 
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) is a water-
soluble yellow dye substance. The mitochondrial dehydrogenase from 
viable cells cleaves the tetrazolium ring of the pale yellow MTT and forms 
violet formazan crystals as shown in Fig. 6. This reduction product is 
water-insoluble. The violet formazan crystals are largely impermeable to 
cell membrane which leads to their accumulation inside the healthy cells. 
For measurement, the formazan crystals are dissolved by a mixture of 
50 mL isopropranol and 165 µL of 1 N HCl. The number of surviving cells 
is directly proportional to the concentration of the formazan product 
formed as determined by a simple colorimetric assay. A multiwell scanning 
spectrophotometer was used for quantification.  
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Figure 6. Reaction of MTT in mitochondria of living cells 
Determination of a suitable initial cell number  
The initial number of cells for plating is different for each type of tumour 
cells. An initial experiment was conducted to ensure that the well surfaces 
did not become over-confluent by the medulloblastoma cells at the end of 
the 72 h incubation period.  
The suitable initial number of the D-425med cells for MTT assay (3 days 
incubation) were determined as follow. The cells were incubated in a T-
flask with a surface area of 25 cm2 until they formed a monolayer. The 
medium was removed and the cells were detached from the T-flask by 
slightly flushing with 10 mL of fresh medium. The number of cells was 
measured by using the CasyTM1 cell counter and recorded as the respective 
cell suspension concentration (cells/mL). 20 % (2 mL) of this suspension 
was further incubated in a T-flask with the same surface area (25 cm2). If 
the seeded cells (20 % of the monolayer) needed around three days to form 
a new monolayer then 20 % of the cell number were regarded as the 
suitable initial number for plating. If the seeded cells (20 % of the 
monolayer) needed around 4 - 5 days to form a new monolayer then the 
suitable initial number of the cells for plating should be more than 30 % of 
the cell number in the monolayer phase. If the seeded cells (20 % of the 
monolayer) needed only around 1-2 day to form a new monolayer then the 
suitable initial number of the cells for plating should be below 20 % of the 
cell number in the monolayer phase.  
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Determination of the EC
50
 of etoposide 
Solutions of 10-8.0, 10-7.0, 10-6.0, 10-5.0, 10-4.5, 10-4.0, and 10-3.75 M etoposide 
were obtained by 10-fold serial dilutions with medium. The cells were 
suspended in cultured medium using an initial cell concentration of 3.31 x 
105 cells/mL. 90 µL aliquots of the cell suspension were dispensed into 96 
well plates and kept at least 10 h in a humidified incubator with 5 % CO
2
 at 
37 ºC. 10 µL of each etoposide solution were added into the wells 
preparing each concentration in twelve-plicate. The first row of the multi-
well plate was used as a blank control to which 10 µL of etoposide-free 
cultured medium were added. Then the medulloblastoma cells were 
incubated with etoposide until 72 h in the incubator. At the end of the 
incubation time, 20 µL of a MTT (5 mg/mL) solution were added to each 
well containing cells. The culture plate was further incubated around 1 h 
until the formazan crystals appeared. Then the crystals were dissolved with 
150 µL of a mixture of 50 mL isopropranol and 165 µL of 1 N HCl. The 96-
well culture plate was left at least 2 h in the refrigerator. Then the colour 
from formazan was measured by using the PolarstarTM-Galaxy photometer 
and wavelengths of 595 and 690 nm. The absorption values at 595 nm 
were corrected by the respective absorption values at 690 nm, in order to 
subtract the effect of the interfering background such as cell components 
and protein. Data analysis was performed by using the GraphPad PrismTM 
program, version 4.0 (GraphPad Software Inc., San Diego, USA). Absorption 
of formazan was plotted against etoposide concentration on a semi-log 
scale. The EC
50
 value which is the etoposide concentration required to kill 
50 % of the cells was estimated by nonlinear regression.  
3.2.7 Colony forming assay 
Effect of concentration and duration of exposure 
The colony forming assay was used to investigate the dependence of 
etoposide antiproliferative activity on concentration and duration of 
exposure. Cells in exponential growth were seeded into a 6-well plate 
Materials and Methods          44 
 
(400 cells in 4 mL medium per well). Then the cells were kept overnight in 
the incubator in order to let them adhere to the surface of the culture plate. 
Etoposide solutions were prepared in medium with different 
concentrations 20 times higher than the final concentrations. 1 mL of each 
etoposide solution was added into each well of the cell suspension in order 
to obtain final etoposide concentrations of 2 x 10-8.0, 2 x 10-7.0, 2 x 10-6.8 ,2 
x 10-6.75, 2 x 10-6.65, 2 x 10-6.4, 2 x 10-6.25, 2 x 10-6.1, 2 x 10-6.0, 2 x 10-5.0 M for 
incubation time 12 h, concentrations of 1 x 10-8.0, 1 x 10-7.0, 1 x 10-6.8, 1 
x10-6.75, 1 x 10-6.65, 1 x 10-6.4, 1 x 10-6.25, 1 x 10-6.1, 1 x 10-6.0, 1 x 10-5.0 M for 
incubation time 24 h and concentrations of 1/5 x 10-8.0, 1/5 x 10-7.0, 1/5 x 
10-6.8, 1/5 x 10-6.75, 1/5 x 10-6.65, 1/5 x 10-6.4, 1/5 x 10-6.25, 1/5 x 10-6.1, 1/5 x 
10-6.0, 1/5 x 10-5.0 M for incubation time 120 h. Each concentration was 
investigated in triplicate. The cells incubated in etoposide-free medium 
were used as controls. Fresh medium containing etoposide was supplied 
daily for the exposure of 120 h to circumvent possible instability of 
etoposide. At the end of the exposure time, the cells were washed twice in 
PBS and kept in a freshly prepared etoposide-free medium. On day 8, 
colonies were washed with cold PBS, fixed with methanol and then stained 
with stain solution (Giemsa colour + crystal violet, s. 3.2.3). The colonies 
were counted by eye under microscopic examination. Each colony was 
composed of at least 40 cells.  
The numbers of colonies in the drug-treated plates were expressed as a 
percentage of the control plates, which were given the value of 100 %. The 
mean ± SD of colony counts from replicate experiments (n = 3) were 
calculated, and survival curves were plotted by using the GraphPad PrismTM 
program on a semi-logarithmic scale with the percentage remaining 
colonies against drug concentration. The antiproliferative effect of 
etoposide concentration and incubation duration were expressed as EC
50
 
and AUC
50
 values. The EC
50
 was the etoposide concentration required to 
inhibit colony formation by 50 %. The AUC
50
 was the total drug exposure 
(duration x concentration) required to inhibit colony formation by 50 %. 
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Simulation of concentration-time profiles 
The colony forming assay was used to investigate the dependence of the 
antiproliferative effect of etoposide on drug schedule by using an in vitro 
dilution model. The medulloblastoma cells were seeded into a 6-well plate 
(400 cells in 4 mL medium per well) and kept overnight in the incubator in 
order to let them adhere to the surface. The cells were exposed to the 
etoposide concentrations which simulated mean concentration-time 
profiles in CSF after intraventricularly administered etoposide 
0.25 mg/12 h and 0.5 mg/24 h.  
The concentration-time profiles were generated by a stepwise dilution 
method. On day 1, at 0 h, 1 mL of different concentrated etoposide 
solutions in medium were added into the wells to obtain the desired 
concentrations. At each pre-determined time-point of the simulated 
concentration-time profiles, culture medium was withdrawn and replaced 
by etoposide-free medium. The withdrawn and replaced volume of medium 
for each time-point was calculated by equation 23. 
 
i
totalii
aceddrawn/repl C
V)C(CV ⋅−= +1
 (eq.23) 
Where: 
V
drawn/replaced
 = withdrawn / replaced volume [mL] 
C
i
 = Concentration at time i [h] 
C
i+1
 = Pre-determined concentration at the 
next time-point (after time i) [h] 
V
total
 = Total volume (5 mL) 
 
The complete stepwise dilution protocols are shown in Appendix B3. At the 
last time-points (at every 12 or 24 h) of each profile, fresh etoposide 
solution was added into the system in order to simulate the next 
administration of etoposide in vivo. The medium was not completely 
removed in order to prevent the cells from stress due to a short-term lack 
of medium. Therefore, only 1.5 mL of culture medium were drawn and 
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replaced with 1.5 mL of different concentrated etoposide solutions which 
were prepared in medium to obtain the pre-determined concentrations. 
The concentrations of the etoposide solutions are presented in Appendix 
B3. After the incubation time (5 days), cells were washed twice in PBS and 
kept in freshly prepared etoposide-free medium.  
On day 8, colonies were stained with stain solution (Giemsa colour + 
crystal violet, s. 3.2.3) and counted by eye under microscopic examination. 
Each colony was composed of at least 40 cells. The numbers of colonies in 
the drug-treated plates were expressed as percentage of the control plates, 
which were given the value of 100 %. The percentage remaining colonies 
were plotted against total drug exposure (AUC) by using Microsoft ExcelTM 
and compared between the two dosage regimens.  
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4. Results 
4.1 HPLC analysis of etoposide in CSF 
Etoposide concentrations in CSF were determined by using HPLC with 
electrochemical detection. As the method was already fully validated at the 
Free University of Berlin, a partial validation was performed. All validation 
experiments were conducted in 0.9% NaCl as in this matrix results were 
comparable to CSF (s. 3.1.3). The validation results as shown below 
demonstrated that the HPLC method was suitable for measuring the 
concentrations of etoposide in CSF. 
4.1.1 Selectivity  
Typical blank chromatograms of CSF, buffer/NaCl, a spiked etoposide 
chromatogram, and a chromatogram of a patient’s CSF sample are shown 
in Fig. 7, 8, 9 and 10, respectively. Retention time of etoposide ranged 
from 6.7 to 7.0 minutes. There was no interference from endogenous 
substances of pooled CSF, buffer and NaCl at this range of the retention 
time. The results indicate that the HPLC analysis method is selective for 
determining etoposide concentrations in CSF.  
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Figure 7. Representative blank HPLC chromatogram of pooled CSF without 
etoposide    
Minutes
0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0 4,5 5,0 5,5 6,0 6,5 7,0 7,5 8,0
Vo
lts
-0,15
-0,10
-0,05
0,00
0,05
0,10
0,15
Vo
lts
-0,15
-0,10
-0,05
0,00
0,05
0,10
0,15
ECDCHA
Blank@07nov03
 
 
Figure 8. Representative blank HPLC chromatogram of 0.02 M phosphate 
buffer mixed with 0.9% NaCl (1:2 V/V) 
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Figure 9. Representative HPLC chromatogram of spiked etoposide 
0.80 µg/mL in 0.02 M phosphate buffer mixed with 0.9% NaCl (1:2 V/V) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 10. Representative HPLC chromatogram of etoposide in patient’s 
CSF (determined concentration 1.18 µg/mL) 
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4.1.2 Linearity 
Linearity was evaluated at five sensitivities of the electrochemical detector 
with five different concentration ranges. Each calibration curve contained 
six calibrators. Linearity was determined by plotting a standard curve 
using peak height versus the corresponding etoposide concentration in the 
sample. A linear regression least squares analysis was performed in order 
to determine the slope, intercept and correlation coefficient of the 
standard curve. The calibration curves were fitted using a weighting factor 
of 1/x. The results are shown in Tab. 5. The coefficients of correlation on 
six different days were higher than 0.99 except at sensitivity 50 nA. 
 
Table 5. Coefficients of correlation of calibration curves at different 
sensitivities (n = 6) 
Sensitivity 
Concentration range 
[µg/mL] 
Correlation coefficient 
(r) 
50 nA 0.05 – 0.20 0.9513 – 0.9967 
2 µA 2.50 – 6.88 0.9981 – 0.9998 
5 µA 6.25 – 17.50 0.9909 – 0.9980 
10 µA 15.00 – 35.00 0.9957 – 0.9998 
20 µA 30.00 – 100.00 0.9928 – 0.9961 
 
4.1.3 Accuracy 
Within-day accuracy  
Within-day accuracy of the assay was calculated by comparing the 
measured concentration of spiked etoposide samples with the 
corresponding nominal concentration. Two concentrations of etoposide 
were measured at the sensitivities 50 nA and 20 µA in six replications 
within the same days. The accuracy was expressed as % RE. The within-day 
accuracy results are shown in Tab. 6. All the values obtained were within 
the limits regarded as acceptable for analysis of biological samples74. 
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Table 6. Within-day accuracy of etoposide (n = 6) 
Sensitivity 
Concentration 
[µg/mL] 
% RE 
0.10 (-2.67) - (+7.77) 
50 nA 
0.18 (-5.85) - (+14.31) 
40.00 (-12.93) - (-2.03) 
20 µA 
80.00 (-1.33) - (+0.76) 
 
Between-day accuracy 
Between-day accuracy of the assay was also calculated by comparing the 
measured concentration of spiked etoposide samples with the 
corresponding nominal concentration. Two concentrations of etoposide 
were measured for each sensitivity (50 nA, 2 µA, 5µA, 10 µA, and 20 µA) 
once per day on subsequent six days. The accuracy was expressed as % RE. 
The between-day accuracy results are shown in Tab. 7. All the values 
obtained were within the limits regarded as acceptable for analysis of 
biological samples74. 
 
Table 7. Between-day accuracy of etoposide (n = 6) 
Sensitivity 
Concentration 
[µg/mL] 
% RE 
0.10 (-13.69) - (+12.76) 
50 nA 
0.18 (-12.00) - (+3.34) 
2.50 (-3.60) - (+5.20) 
2 µA 
5.00 (-2.40) - (+2.40) 
7.50 (-10.27) - (+1.47) 
5 µA 
10.00 (-0.70) - (+7.50) 
20.00 (+0.70) - (+4.70) 
10 µA 
32.50 (-10.28) - (+7.48) 
40.00 (-7.20) - (+4.65) 
20 µA 
80.00 (-4.76) - (+1.48) 
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4.1.4 Precision 
Within-day precision  
Within-day precision of the assay was determined as coefficient of variation. 
Two concentrations of spiked etoposide samples were measured at the 
sensitivities 50 nA and 20 µA in six replications on the same days. The 
within-day precision results are shown in Tab. 8. All the values obtained 
are within the limits regarded as acceptable for analysis of biological 
samples74.  
 
Table 8. Within-day precision of etoposide (n = 6) 
Sensitivity 
Concentration 
[µg/mL] 
% CV 
0.10 3.70 
50 nA 
0.18 8.36 
40.00 3.77 
20 µA 
80.00 0.76 
 
 
Between-day precision  
Between-day precision of the assay was also determined as coefficient of 
variation. Two different concentrations of etoposide were measured for 
each sensitivity (50 nA, 2 µA, 5 µA, 10 µA and 20 µA) in six replications on 
six different days. The between-day precision results are shown in Tab. 9. 
All the values obtained are within limits regarded as acceptable for analysis 
of biological samples74.  
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Table 9. Between-day precision of etoposide (n = 6) 
Sensitivity 
Concentration 
[µg/mL] 
% CV 
0.10 13.83 
50 nA 
0.18 6.04 
2.50 3.77 
2 µA 
5.00 2.13 
7.50 4.59 
5 µA 
10.00 2.66 
20.00 1.58 
10 µA 
32.50 6.04 
40.00 4.06 
20 µA 
80.00 5.30 
 
4.2 Pharmacokinetics of etoposide in CSF after 
intraventricular administration 
4.2.1 Concentration-time profiles 
Fig. 11, 12 and 13 show mean CSF concentration-time profiles following 
etoposide ivc administration of three different dosage regimens 
(0.25 mg/12 h, 0.50 mg/24 h and 1.0 mg/24 h, respectively) on five 
consecutive days. Fig. 14 shows the mean concentration-time profiles of 
etoposide in CSF following all dosage regimens. There was no drug 
accumulation in CSF after repeated ivc administration of etoposide during 
one cycle. 
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Figure 11. Mean CSF concentration-time profile following ivc 
administration of etoposide 0.25 mg/12 h on five consecutive days (2 
patients, 8 cycles) 
The diagram does not show standard deviations because data were 
obtained from only two patients. 
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Figure 12. CSF concentration-time profile (mean ± SD) following ivc 
administration of etoposide 0.50 mg/24 h on five consecutive days (8 
patients, 41 cycles) 
Standard deviation is not shown when lower value was below zero. 
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Figure 13. CSF concentration-time profile (mean ± SD) following ivc 
administration of etoposide 1.0 mg/24 h on five consecutive days (14 
patients, 73 cycles) 
Standard deviations (*) were not shown because data were obtained from 
only one patient. 
Standard deviations were not shown when lower values were below zero. 
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Figure 14. Mean concentration-time profiles of etoposide in CSF after ivc 
administration of three different dosage regimens 
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4.2.2 Generation of population parameters 
First, the population values for the model parameters V
c
, λ
z
, r
c
 and λ
1
were 
estimated from data of seven patients undergoing full sampling as 
described in 3.1.9. The results are summarised in Tab. 10. The 
concentration-time profiles of these patients are shown in Appendix A2. 
 
Table 10. Individual model parameters for Bayesian curve fitting  
Patient Cycle 
Dosage 
regimen 
V
c
 
[L] 
λ
z
  
[h-1] 
r
c
  
 
λ
1
  
[h-1] 
1 9 1 mg/24 h 0.0358 0.1215 0.0523 1.7438 
11 1 1 mg/24 h 0.0407 0.0948 0.0231 0.7468 
15 1 1 mg/24 h 0.0674 0.0707 0.0999 0.6168 
4 1 0.5 mg/24 h 0.1509 0.0965 0.0899 1.3370 
5 1 0.5 mg/24 h 0.0893 0.1083 0.0415 0.6461 
8 1 0.5 mg/24 h 0.0201 0.1272 0.2081 2.2527 
9 1 0.5 mg/24 h 0.0619 0.1080 0.1702 0.4039 
 
By using the Mann-Whitney U test, no statistical difference was found 
between the individual model parameters obtained from etoposide 
0.5 mg/24 h and those obtained from etoposide 1.0 mg/24 h as shown in 
Tab. 11. Thus, the population parameters were obtained from both dosage 
regimens as mean and SD values of the individual model parameters from 
the seven patients as shown in Tab. 12.  
Table 11. Comparison of parameters between the two dosage regimens 
(etoposide 0.5 mg/24 h and 1.0 mg/24 h) by using the Mann-Whitney U 
test 
Model parameter  Statistical significance (p value) 
V
c
 [L] 0.629 
λ
z
 [h-1] 0.229 
r
c
  0.114 
λ
1
 [h-1] 0.857 
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Table 12. Population parameters used for Bayesian curve fitting  
Model parameter Mean SD CV [%] 
V
c
 [L] 0.0666 0.0436 65.5382 
λ
z
 [h-1] 0.1039 0.0188 18.1358 
r
c
 0.0979 0.0687 70.1753 
λ
1
 [h-1] 1.1067 0.6889 62.2505 
 
4.2.3 Individual Bayesian curve fitting 
Fig. 15, 16 and 17 show examples of CSF concentration-time profiles of 
etoposide 0.25 mg/12 h, 0.50 mg/24 h and 1.0 mg/24 h evaluated with 
SipharWinTM by using a two-compartment model and Bayesian curve fitting. 
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Figure 15. CSF concentration-time profile of a representative patient who 
received etoposide 0.25 mg/12 h obtained by Bayesian curve fitting 
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Figure 16. CSF concentration-time profile of a representative patient who 
received etoposide 0.50 mg/24 h obtained by Bayesian curve fitting 
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Figure 17. CSF concentration-time profile of a representative patient who 
received etoposide 1.0 mg/24 h obtained by Bayesian curve fitting 
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4.2.4 Pharmacokinetic parameters in CSF 
Individual pharmacokinetic parameters of etoposide 0.25 mg/12 h, 
0.50 mg/24 h and 1.0 mg/24 h are shown in Tab. 13 - 15, respectively. 
Etoposide pharmacokinetic parameters from all dosage regimens are 
summarised as means ± SD in Tab. 16 by excluding one patient receiving 
etoposide 0.25 mg/12 h who had a hydrocephalus complication (s. 4.2.6). 
Individual pharmacokinetic data for each cycle are presented in Appendix 
A3. C
min
, C
max
 and total area under the concentration-time curve in one cycle 
(AUC
total
) of etoposide 1 mg/24 h were approximately two-fold higher than 
those observed after etoposide 0.5 mg/24 h indicating that CSF 
concentrations increase proportionally with etoposide dose. Because of the 
shorter dosage intervals mean C
min
 after etoposide 0.25 mg/12 h was 
higher than that obtained after etoposide 0.5 mg/24 h. Tab. 13 - 16 show 
the large coefficients of variation of pharmacokinetic parameters of 
etoposide at any given dose in CSF indicating a high inter- and 
intraindividual variability in CSF disposition of etoposide after ivc 
administration.  
4.2.5 Effect of dosage regimen on pharmacokinetic 
parameters 
Fig. 18, 19 and 20 show the pharmacokinetic parameters t
1/2z
, V
ss
 and CL as 
box plots. Median values of pharmacokinetic parameters after all dosage 
regimens were similar. Furthermore, no statistically significant differences 
of pharmacokinetic parameters among the three different dosage 
regimens were found by using the Kruskul-Wallis test (s. Tab. 16). This 
result indicates that etoposide pharmacokinetics in CSF is dose- and 
schedule- independent in the dose range studied. 
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Table 13. Individual pharmacokinetic parameters of etoposide in CSF 
(intraindividual mean ± SD; % CV in brackets) after ivc administration of 
0.25 mg/12 h 
Patient 1 2 * 3 ** 
No. of cycles 4 1 3 
AUC
total
 
[µg x h/mL] 
115.29 ± 6.52 
(5.66) 
139.70 
111.45 ± 62.66 
(56.22) 
CL 
[mL/min]  
0.36 ± 0.02 
(5.45) 
0.30 
0.45 ± 0.21 
(46.96) 
V
ss
 
[L]  
0.10 ± 0.02 
(15.93) 
0.13 
0.24 ± 0.19 
(77.02) 
C
min
  
[µg/mL]  
0.17 ± 0.03 
(17.88) 
0.37 
0.37 ± 0.16 
(41.85) 
C
max
  
[µg/mL]  
6.15 ± 1.06 
(17.23) 
3.61 
0.72 ± 0.42 
(58.35) 
t
1/2λ1 
[h-1]  
0.74 ± 0.07 
(9.76) 
0.54 
0.53 ± 0.12 
(22.82) 
t
1/2z
 
[h-1] 
6.56 ± 0.06 
(0.85) 
7.21 
7.83 ± 1.35 
(17.23) 
* The SD is not shown because the patient received only one cycle. 
** The patient exhibited a hydrocephalus (s. 4.2.6). 
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Table 14. Individual pharmacokinetic parameters of etoposide in CSF 
(intraindividual mean ± SD; % CV in brackets) after ivc administration of 
0.5 mg/24 h 
Patient 1 4 * 5 * 6 
No. of cycles 5 1 1 16 
AUC
total
 
[µg x h/mL] 
119.71 ± 32.42 
(27.08) 
54.03 34.11 
258.34 ± 130.87 
(22.21) 
CL 
[mL/min]  
0.37 ± 0.11 
(29.46) 
0.77 1.22 
0.21 ± 0.12 
(22.19) 
V
ss
 
[L]  
0.12 ± 0.04 
(30.54) 
0.18 0.38 
0.06 ± 0.05 
(0.31) 
C
min
  
[µg/mL]  
0.11 ± 0.03 
(27.89) 
0.02 0.03 
0.10 ± 0.06 
(13.55) 
C
max
  
[µg/mL]  
10.38 ± 2.26 
(21.76) 
3.08 2.56 
27.52 ± 15.04 
(0.84) 
t
1/2λ1 
[h-1]  
0.70 ± 0.07 
(10.32) 
0.81 0.47 
0.66 ± 0.06 
(2.73) 
t
1/2z
 
[h-1] 
6.72 ± 0.11 
(1.60) 
6.47 6.64 
6.53 ± 0.09 
(1.43) 
* The SD is not shown because the patients received only one or two cycles. 
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Table 14.-continued 
Patient 7* 8* 9 10 
No. of cycles 2 2 8 6 
AUC
total
 
[µg x h/mL] 
157.53 170.97 
143.30 ± 22.28 
(15.55) 
196.46 ± 50.36 
(25.63) 
CL 
[mL/min]  
0.27 0.25 
0.30 ± 0.05 
(16.57) 
0.23 ± 0.06 
(27.14) 
V
ss
 
[L]  
0.07 0.10 
0.12 ± 0.03 
(28.28) 
0.08 ± 0.02 
(25.28) 
C
min
  
[µg/mL]  
0.06 0.21 
0.18 ± 0.04 
(21.10) 
0.16 ± 0.10 
(58.28) 
C
max
  
[µg/mL]  
17.24 9.65 
8.28 ± 2.96 
(35.72) 
16.40 ± 3.66 
(22.33) 
t
1/2λ1 
[h-1]  
0.69 0.79 
0.99 ± 0.45 
(45.81) 
0.65 ± 0.02 
(3.12) 
t
1/2z
 
[h-1] 
6.46 6.96 
7.24 ± 1.25 
(17.33) 
7.03 ± 0.81 
(11.55) 
* The SD is not shown because the patients received only one or two cycles. 
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Table 15. Individual pharmacokinetic parameters of etoposide in CSF 
(intraindividual mean ± SD; % CV in brackets) after ivc administration of 
1.0 mg/24 h 
Patient 1 11 12* 13 
No. of cycles 6 6 1 27 
AUC
total
 
[µg x h/mL] 
199.34 ± 75.12 
(37.68) 
176.26 ± 39.62 
(22.48) 
286.98 
201.95 ± 56.88 
(28.16) 
CL 
[mL/min]  
0.49 ± 0.23 
(47.70) 
0.50 ± 0.15 
(30.15) 
0.29 
0.44 ± 0.12 
(27.43) 
V
ss
 
[L]  
0.15 ± 0.08 
(51.38) 
0.14 ± 0.04 
(28.60) 
0.11 
0.14 ± 0.04 
(28.23) 
C
min
  
[µg/mL]  
0.13 ± 0.05 
(38.58) 
0.15 ± 0.08 
(51.43) 
0.25 
0.20 ± 0.27 
(134.16) 
C
max
  
[µg/mL]  
18.41 ± 4.34 
(23.56) 
27.42 ± 11.92 
(43.48) 
23.46 
18.33 ± 4.96 
(27.05) 
t
1/2λ1 
[h-1]  
0.67 ± 0.08 
(11.30) 
0.67 ± 0.10 
(14.39) 
0.67 
0.66 ± 0.02 
(2.49) 
t
1/2z
 
[h-1] 
6.49 ± 0.21 
(3.24) 
6.88 ± 0.54 
(7.87) 
7.00 
6.62 ± 0.09 
(1.38) 
* The SD is not shown because the patients received only one or two cycles. 
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Table 15.-continued 
Patient 14 15 16* 17* 18* 
No. of 
cycles 
4 3 1 2 1 
AUC
total
 
[µg x h/mL] 
515.53 ± 109.89 
(21.32) 
250.20 ± 92.34 
(36.90) 
160.99 201.91 118.72 
CL 
[mL/min]  
0.17 ±  0.03 
(17.70) 
0.37 ± 0.14 
(37.96) 
0.52 0.41 0.70 
V
ss
 
[L]  
0.12 ± 0.02 
(12.42) 
0.20 ± 0.10 
(50.92) 
0.12 0.16 0.22 
C
min
  
[µg/mL]  
1.41 ± 0.47 
(33.20) 
0.66 ± 0.14 
(21.51) 
0.06 0.20 0.03 
C
max
  
[µg/mL]  
23.13 ± 1.99 
(8.61) 
15.78 ± 8.81 
(55.84) 
21.44 12.76 n.a. 
t
1/2λ1 
[h-1]  
0.49 ± 0.03 
(5.70) 
0.55 ± 0.06 
(11.78) 
0.64 0.67 0.63 
t
1/2z
 
[h-1] 
10.13 ± 0.57 
(5.62) 
8.07 ± 0.87 
(10.73) 
6.39 7.05 6.58 
* The SD is not shown because the patients received only one or two cycles. 
n.a. = not available 
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Table 15.-continued 
Patient 19* 20 21 22* 23 
No. of cycles 2 3 6 2 9 
AUC
total
 
[µg x h/mL] 
155.42 
143.31±45.81 
(31.97) 
147.27±66.64 
(45.25) 
215.28 
360.93±142.30 
(39.42) 
CL 
[mL/min]  
0.56 
0.63±0.25 
(39.00) 
0.67±0.28 
(41.94) 
0.39 
0.27±0.11 
(42.27) 
V
ss
 
[L]  
0.18 
0.18±0.08 
(45.86) 
0.22±0.11 
(49.56) 
0.15 
0.13±0.02 
(14.58) 
C
min
  
[µg/mL]  
0.04 
0.07±0.01 
(8.62) 
0.09±0.02 
(24.27) 
0.34 
1.04±0.80 
(76.68) 
C
max
  
[µg/mL]  
16.77 
15.20±0.60 
(3.97) 
13.27±6.64 
(50.01) 
16.89 
20.63±2.87 
(13.93) 
t
1/2λ1 
[h-1]  
0.65 
0.75±0.19 
(25.27) 
0.62±0.07 
(10.70) 
0.63 
0.56±0.07 
(12.91) 
t
1/2z
 
[h-1] 
6.60 
6.38±0.19 
(2.95) 
6.63±0.10 
(1.49) 
6.91 
8.43±1.55 
(18.35) 
* The SD is not shown because the patients received only one or two cycles. 
 
 
 
 
 
 
 
 
 
 
Results           67 
 
Table 16. Mean pharmacokinetic parameters (± SD; % CV in brackets) of 
etoposide in CSF after intraventricular administration of three different 
dosage regimens  
 
 
0.25 mg / 12 h 
* 
 
0.50 mg / 24 h 
 
 
1.0 mg / 24 h 
 
No. of 
patients 
2 8 14 
No. of cycles 5 41 73 
p value 
Kruskal-
Wallis 
test 
AUC
total
 
[µg x h/mL] 
127.50 
141.81 ± 73.15 
(51.59) 
223.86 ± 105.42 
(47.09) 
0.038 
CL 
[mL/min]  
0.33 
0.45 ± 0.36 
(79.96) 
0.45 ± 0.16 
(34.02) 
0.168 
V
ss
 
[L]  
0.11 
0.14 ± 0.11 
(75.66) 
0.16 ± 0.04 
(23.62) 
0.095 
C
min
  
[µg/mL]  
0.27 
0.11 ± 0.07 
(69.54) 
0.33 ± 0.42 
(22.98) 
0.198 
C
max
  
[µg/mL]  
4.89 
11.89 ± 8.27 
(64.35) 
18.73 ± 4.30 
(124.60) 
0.020 
t
1/2λ1 
[h-1]  
0.64 
0.72 ± 0.15 
(20.58) 
0.63 ± 0.06 
(10.04) 
0.180 
t
1/2z
 
[h-1] 
6.88 
6.76 ± 0.29 
(4.28) 
7.15 ± 1.05 
(14.66) 
0.906 
*The SD is not shown because the mean value was calculated from only 
two patients. 
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D1: Etoposide 0.25 mg/12 h; D2: Etoposide 0.50 mg/24 h; D3: Etoposide 1.0 mg/24 h 
 
Figure 18. Box plot of elimination half-lives after three different dosage 
regimens of ivc etoposide 
 
 
1482N =
D3D2D1
V
ss
[L
]
0.5
0.4
0.3
0.2
0.1
0.0
5
V
ss
[L
]
 
D1: Etoposide 0.25 mg/12 h; D2: Etoposide 0.50 mg/24 h; D3: Etoposide 1.0 mg/24 h 
 
Figure 19. Box plot of volumes of distribution after three different dosage 
regimens of ivc etoposide 
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D1: Etoposide 0.25 mg/12 h; D2: Etoposide 0.50 mg/24 h; D3: Etoposide 1.0 mg/24 h 
 
Figure 20. Box plot of clearances after three different dosage regimens of 
ivc etoposide 
 
4.2.6 Case report of a patient with hydrocephalus  
The effect of a hydrocephalus complication on the CSF disposition of 
etoposide was studied in three cycles in one patient. The pharmacokinetic 
parameters of this patient are summarised in Tab. 17. The V
ss
 (0.24 ± 
0.19 L) in this patient was higher than those found in other patients (0.11 
± 0.02 L) who received etoposide with the same dosage regimen 
(0.25 mg/12 h). The difference between C
max
 and C
min
 was small in this 
patient.  
 
 
 
 
 
Results           70 
 
Table 17. Pharmacokinetic parameters of one patient with hydrocephalus 
during ivc administration of etoposide 0.25 mg/12 h 
Pharmacokinetic parameter Mean ± SD 
(n = 3) 
C
max
 [µg/mL] 0.72 ± 0.42 
C
min
 [µg/mL] 0.37 ± 0.16 
AUC
total
 [µg x h/mL] 111.45 ± 62.66 
CL [mL/min] 0.45 ± 0.21 
V
ss
 [L] 0.24 ± 0.19 
t
1/2z
 [h] 7.83 ± 1.35 
 
 
4.2.7 Distribution of etoposide inside the CSF 
In order to study the distribution of etoposide inside the CSF compartment, 
CSF samples (n = 12) from four patients were taken simultaneously from 
an Ommaya reservoir (OMR) and by lumbar puncture four hours after 
etoposide ivc administration via the OMR. Etoposide concentrations of CSF 
samples collected from the OMR were similar to etoposide concentrations 
of samples collected by lumbar puncture (s. Tab. 18 and Fig. 21). By using 
paired t-test, no significant difference (p = 0.988) of etoposide 
concentrations in CSF was found between the two groups. The results 
indicate that etoposide is well distributed in the CSF compartment four 
hours after ivc administration via the OMR.  
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Table 18. Etoposide concentrations in CSF samples drawn from an OMR 
and by lumbar puncture (LP) four hours after etoposide ivc administration 
via OMR 
Patient no. / Cycle Etoposide concentration 
[µg/mL] 
0.25 mg/12 h OMR LP 
Patient 1/ Cycle 5 0.54 0.47 
Patient 1 / Cycle C 0.51 0.61 
Patient 1 / Cycle 3 0.42 0.58 
Patient 3 / Cycle 2 0.21 0.24 
0.5 mg/24 h   
Patient 8 / Cycle 1 2.77 2.34 
Patient 8 / Cycle 2 1.58 0.81 
Patient 1 / Cycle 1 0.61 0.84 
Patient 1 / Cycle 2 0.94 0.73 
1.0 mg/24 h   
Patient 1 / Cycle 6 0.82 1.28 
Patient 1 / Cycle 8 1.06 0.80 
Patient 11 / Cycle 1 1.51 1.67 
Patient 11 / Cycle 2 0.94 1.57 
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Figure 21. Comparison of etoposide concentrations in CSF samples drawn 
from an OMR and by lumbar puncture (LP) four hours after ivc 
administration via an OMR (n = 12 from 4 patients) 
 
4.3 Stability of etoposide in cell culture medium 
Stability of etoposide in cell culture medium (DMEMTM with GlutaMaxTM) was 
investigated as basis of the planned in vitro experiments. Etoposide 
30 µg/mL in culture medium was incubated at 37 ºC for up to 72 h. 
Samples were collected at 0, 1, 2, 4, 8, 12, 24, 31, 48, and 72 h, 
respectively. Etoposide concentrations in medium were measured by HPLC 
with UV detection. The results in Tab. 19 show that the concentrations of 
etoposide remain for 48 h above 90 % of the initial concentration. At 72 h, 
the concentration of etoposide in DMEMTM with GlutaMaxTM under cell 
incubator conditions was only about 80 % of the initial concentration.   
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Table 19. Etoposide stability under cell incubator conditions (initial 
concentration was set to 100 %) 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Cytotoxic activity of etoposide in medullo-
blastoma cells 
First, the optimal initial number of D-425med medulloblastoma cells for 
seeding was determined for the MTT assay on a 96-well culture plate. The 
cells were incubated in a T-flask with a surface area 25 cm2 until they 
formed a monolayer. 20 % of the cells of the monolayer were further 
incubated in a T-flask with the same surface area (25 cm2). The cells 
needed around five days to form a monolayer again in the T-flask. As 
described in 3.2.6, 30 % of the cell number from the monolayer phase 
were hence regarded as the suitable initial seeding number for D-425med 
cells on 96-well plate. Afterwards, the absolute number of initial cells for 
seeding was calculated. The number of cells used to form the first 
monolayer in the T-flask 25 cm3 (100 %) was 7.88 x 105 cells/mL. Therefore, 
the equivalent number of cells for 96-well plate with a surface area of 
35 cm2 would be 1.10 x 106 cells/mL. As 30 % was determined as optimal 
for seeding, the suitable initial number of D-425med cells for the MTT 
Time 
[h] 
% remaining etoposide 
1 106.61 
2 99.21 
4 109.86 
8 107.90 
12 104.98 
24 103.27 
31 97.46 
48 94.51 
72 80.77 
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assay in 96-well plates was hence 3.31 x 105 cells/mL.  
Then, the EC
50
 of etoposide for D-425med cells was determined by using 
the MTT assay. The D-425med cells of the 16th passage were incubated 
with etoposide in a concentration range of 10-8 to 10-3.75 M for 72 h. The 
results are shown in Fig. 22. The EC
50
 of etoposide in D-425med cells was 
found to be 0.25 ± 0.02 µg/mL or 4.26 x 10-7 ± 0.32 x 10-7 M, respectively. 
Individual data of the MTT assay are shown in Appendix B1. 
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Figure 22. Concentration-effect relationship of etoposide in D-425med 
cells determined by using the MTT assay (n = 12) 
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4.5 Antiproliferative activity of etoposide in 
medulloblastoma cells 
4.5.1 Effect of concentration and duration of exposure 
For the colony forming assay, D-425med cells were incubated with 
different etoposide concentrations but the total drug exposures (AUC, 
concentration x time) were kept constant. Etoposide concentrations ranged 
from 2 x 10-8 to 2 x 10-5 M for an incubation period of 12 h, from 1 x 10-8 
to 1 x 10-5 M for an incubation period of 24 h and from 1/5 x 10-8 to 1/5 x 
10-5 M for an incubation period of 120 h.  
The results are shown in Tab.20 and Fig. 23. The EC
50
 of etoposide at an 
incubation time of 12 h was around two-fold higher than those obtained 
from incubation times 24 h and 120 h. The AUC
50
 was comparable among 
the three groups. These results indicate that the growth of 
medulloblastoma cell colonies mainly depends on exposure rather than 
concentration only. The individual data of colony forming assay were 
shown in Appendix B2. 
 
Table 20. EC
50
 and AUC
50
 of etoposide in medulloblastoma cells (D-425med) 
determined by using the colony forming assay (mean ± SD; n = 3) 
Incubation time 
[h] 
EC
50
 
[µg/mL] 
AUC
50
  
 [µg x h/mL] 
12 0.46 ± 0.07 5.54 ± 0.84 
24 0.24 ± 0.03 5.67 ± 0.71 
120 0.20 ± 0.03 4.75 ± 0.84 
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Figure 23. Effect of etoposide exposure on growth rate of medullo-
blastoma cells (D-425med) by using the colony forming assay (n = 3) 
4.5.2 Effect of dosage regimen 
The effect of two dosage regimens (0.25 mg/12 h and 0.50 mg/24 h) on 
etoposide antiproliferative activity was investigated by using an in vitro 
dilution model. The two dosage regimens were simulated in vitro.  
The medulloblastoma cells were incubated with etoposide concentration-
time profiles which were obtained from the pharmacokinetic study. Mean 
concentration-time profiles from both dosage regimens are shown in Tab. 
21. To simulate etoposide concentration-time profiles, the concentrations 
of etoposide were adjusted by stepwise dilution at 0.25, 0.50, 1, 2, 4, 8, 
12 h for etoposide 0.25 mg/12 h and at 0.25, 0.50, 1, 2, 4, 8, 12, 16, 20, 
24 h for etoposide 0.50 mg/24 h. In the clinical study, etoposide was 
given to patients on five consecutive days, hence the cells were incubated 
with 10 repeated concentration-time profiles for twice daily administration 
(etoposide 0.25 mg/12 h) and 5 for once daily administration (etoposide 
0.50 mg/24 h). On day 6, the cells were incubated for further 12 h with 
etoposide concentrations, reflecting the AUC from the last measurable 
concentration to infinity.  
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In order to characterise the pharmacokinetic disposition, two-compartment 
models were fitted to the mean concentration-time profiles of the patients 
after both dosage regimens as shown in Tab. 21. The obtained model 
equations (eq. 15) were used to simulate etoposide concentrations at each 
pre-determined time-point (s. 3.1.9). The simulated concentration-time 
profiles of etoposide 0.25 mg/12 h and etoposide 0.50 mg/24 h are 
shown in Tab. 22 and 23.  
 
Table 21. Mean concentration-time profiles of etoposide 0.25 mg/12 h and 
0.5 mg/24 h obtained from the clinical study 
Etoposide 0.25 mg/12 h Etoposide 0.50 mg/24 h 
Time [h] Conc. [µg/mL] Time [h] Conc. [µg/mL] 
0.25 6.27 0.25 12.16 
0.42 2.90 0.50 4.67 
1.00 1.18 1.11 3.93 
3.79 0.54 2.27 2.36 
12.00 0.11 4.53 1.04 
12.25 6.41 8.05 0.40 
24.00 0.34 12.22 0.26 
24.25 3.52 24.00 0.10 
36.00 0.38 24.25 14.28 
36.25 3.67 48.00 0.17 
48.00 0.32 48.25 15.58 
48.25 2.30 72.00 0.14 
60.00 0.16 72.25 13.80 
60.25 4.11 96.00 0.12 
72.00 0.18 96.25 14.93 
72.25 4.45   
84.00 0.16   
84.25 5.80   
96.00 0.17   
96.25 7.81   
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Table 22. Simulated concentration-time profile after 10 administrations of 
etoposide 0.25 mg/12 h 
Time 
[h] 
Etoposide concentration [µg/mL] 
Admin. 1 2 3 4 5 6 7 8 9 10 Mean 
0.25 4.82 5.00 5.05 5.07 5.07 5.07 5.07 5.07 5.07 5.07 5.04 
0.50 3.78 3.95 4.00 4.02 4.02 4.02 4.02 4.02 4.02 4.02 3.99 
1 2.38 2.55 2.60 2.61 2.62 2.62 2.62 2.62 2.62 2.62 2.58 
2 1.11 1.26 1.30 1.31 1.32 1.32 1.32 1.32 1.32 1.32 1.29 
4 0.48 0.61 0.64 0.65 0.66 0.66 0.66 0.66 0.66 0.66 0.63 
8 0.28 0.36 0.38 0.39 0.39 0.39 0.39 0.39 0.39 0.39 0.38 
12 0.18 0.24 0.25 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.25 
Admin. = Administration 
 
Table 23. Simulated concentration-time profile after 5 administrations of 
etoposide 0.5 mg/12 h 
Time 
[h] 
Etoposide concentration [µg/mL] 
Admin. 1 2 3 4 5 Mean 
0.25 11.88 12.00 12.01 12.01 12.01 11.98 
0.50 9.34 9.46 9.46 9.47 9.47 9.44 
1 5.91 6.02 6.03 6.03 6.03 6.00 
2 2.70 2.80 2.81 2.81 2.81 2.79 
4 1.11 1.18 1.19 1.19 1.19 1.17 
8 0.62 0.67 0.68 0.68 0.68 0.66 
12 0.41 0.44 0.45 0.45 0.45 0.44 
16 0.27 0.29 0.30 0.30 0.30 0.29 
20 0.18 0.20 0.20 0.20 0.20 0.19 
24 0.12 0.13 0.13 0.13 0.13 0.13 
Admin. = Administration 
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In the next step, the expected AUC
total
 was calculated from the simulated 
concentration-time profiles by the trapezoidal rule and compared with the 
AUC
50
 determined in 4.5.1. The AUC
total
 was found to be 127.50 µg x h/mL 
for etoposide 0.25 mg/12 h and 141.81 µg x h/mL for etoposide 
0.5 mg/24 h, respectively. These values were much higher than the AUC
50
 
values (4.75 µg x h/mL) for an incubation period of 120 h indicating that 
the simulated regimens would have been too toxic for the cells. Therefore, 
each concentration of the simulated mean concentration-time profiles was 
reduced by the factors 5, 10, and 15, respectively. The actually used 
concentration-time profiles with reduction factors 5, 10 and 15 are shown 
in Appendix B3. The AUC
total
 values for the in vitro study were calculated 
from the concentration-time profiles by using the trapezoidal rule and 
shown in Tab. 24. 
 
Table 24. AUC
total 
values of actually used etoposide concentration-time 
profiles  
Etoposide 
dosage 
regimen 
AUC
total
 obtained 
with reduction 
factor 15 
[µg x h/mL] 
AUC
total
 obtained 
with reduction 
factor 10 
 [µg x h/mL] 
AUC
total
 obtained 
with reduction 
factor 5 
 [µg x h/mL] 
0.25 mg/12 h 5.60 11.20 16.80 
0.50 mg/12 h 6.73 13.45 20.18 
 
The results of this experiment are shown in Tab. 25 and 26. The 
percentage of colonies remaining was decreased when total drug 
exposures from both dosage regimens increased. A comparison of the 
percentage of colonies remaining between the two dosage regimens at the 
same total drug exposure (AUC) is shown in Fig. 24. More colonies 
remained after incubation with the once daily regimen compared to the 
twice daily regimen at the same exposure to etoposide. These data 
indicate that administration of etoposide 0.25 mg/12 h on five consecutive 
days etoposide may result in a higher antiproliferative activity than 
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administration of etoposide 0.50 mg/24 h both on five consecutive days. 
The individual data of this experiment are shown in Appendix B4. 
 
Table 25. Remaining colonies of D-425med cells after exposure to the 
twice daily dosage regimen for five days 
 % colonies remaining (n = 3) 
Total drug 
exposure 
[µg x h/mL] 
 1 2 3  Mean SD 
5.60  73.17 75.41 69.31  72.63 3.09 
11.20  81.67 57.14 40.96  59.92 20.49 
16.80  25.23 45.83 38.35  36.47 10.43 
 
 
Table 26. Remaining colonies of D-425med cells after exposure to the 
once daily dosage regimen for five days  
 % colonies remaining (n = 3) 
Total drug 
exposure 
[µg x h/mL] 
 1 2 3  Mean SD 
6.73  111.54 92.17 101.20  101.64 9.69 
13.45  69.51 59.26 52.06  60.28 8.72 
20.18  40.87 34.00 41.67  38.85 4.22 
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Figure 24. Antiproliferative activity of etoposide on D-425med cells after 
incubation with a once daily and twice daily regimen over five days (n = 3) 
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5. Discussion 
5.1 Intraventricular administration of etoposide 
The rational for the administration of chemotherapy by the intra-CSF route 
is based on its ability to circumvent the blood-brain barrier, achieve high 
drug concentrations and drug exposure at the principle tumour site and 
minimize systemic drug exposure and systemic toxicity40,44,54. Several 
disadvantages were found with intralumbar drug administration44. Hence 
ivc drug administration is an interesting alternative for intra-CSF therapy. 
The advantages of ivc administration are less pain and inconvenience 
associated with frequent multiple administration, the feasibility of frequent 
multiple–dosing schedules, favourable pharmacokinetics with more 
homogeneous drug distribution within the CSF compartment, and the 
possibility of CSF sampling through the OMR with its catheter tip placed in 
the lateral ventricle40,44. This technique enabled us to measure drug 
concentrations in CSF already shortly after ivc administration.  
Several factors have led to the decision to develop etoposide as an agent 
for ivc administration. First, as a topoisomerase II inhibitor, etoposide has 
a different mechanism of antitumour activity from other agents used for 
intra-CSF therapy such as cytarabine and methotrexate which are classified 
as antimetabolites. Therefore, etoposide offers the potential of activity 
against tumours which are either initially unresponsive to antimetabolites 
or have acquired resistance to them. Second, etoposide is active against 
various tumour cells especially medulloblastoma and PNET. Third, it was 
previously demonstrated that intra-CSF administration of etoposide is 
feasible and safe. Moreover, etoposide is known to have a high protein 
binding in plasma (up to 97 %) which can impair the action of etoposide on 
tumour cells after systemic administration67,68. Therefore, it was supposed 
that etoposide ivc administration can provide higher unbound etoposide 
levels in CNS because of the low protein concentrations in CSF. Under 
physiological conditions the protein concentrations in cerebrospinal fluid 
are less than one percent of the protein content in plasma86. 
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5.2 Pharmacokinetics of etoposide in CSF after ivc 
administration 
The pharmacokinetic data of etoposide in CSF were evaluated using 
Bayesian curve fitting which has some advantages such as estimation of 
pharmacokinetic parameters after sparse sampling. This means that the 
patients were less disturbed by sample collection. Moreover, it can 
minimise the problem of frequent sampling which may interfere with CSF 
dynamics and disturb the distribution of the intraventricularly 
administered drug. The pharmacokinetics of etoposide in CSF after ivc 
administration can be described with a linear two-compartment model as 
published in a previous report from Fleischhack et al.70. The biphasic 
pattern might be the result of different processes such as diffusion along 
the concentration gradient from CSF to brain tissue or blood vessels, 
uptake of drug by receptor-mediated transport into the CNS, and 
elimination of drug by CSF bulk flow 40,87,88 
5.2.1 Peak and trough concentrations  
Mean C
max
, C
min
 and AUC of etoposide in CSF increased proportionally with 
etoposide dose indicating that the disposition of etoposide within the CSF 
depends on processes that are not saturated in the dose range of the 
study. Mean C
max
 (4.89 - 18.73 µg/mL) values from all dosage regimens 
were around 50 to 200 times higher than those obtained after high-dose 
systemic therapy confirming the advantage of regional therapy. Thus, ivc 
administration of etoposide allows a CSF exposure to etoposide that could 
never be achieved with systemic administration. Mean C
min
 (0.11 – 
0.33 µg/mL) values from our study were above the minimum cytotoxic 
concentration of etoposide to neuroblastoma cells from the study of Hill et 
al.12 which reported that the concentration of etoposide required to reduce 
survival of the human neuroblastoma cell line CHP100 to 70 % was 
0.08 µg/mL. Tomlinson et al.11 reported concentrations of etoposide 
required to reduce survival of medulloblastoma cells to 63 % ranging from 
0.11 to 2.24 µg/mL (corresponding to 0.19 - 3.81 µM). The time of 
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exposure to etoposide in most in vitro studies in medulloblastoma and 
neuroblastoma cells was only up to 24 h11,12 whereas the typical clinical 
treatment is intravenous administration of etoposide for 3 - 5 consecutive 
days or orally for 14 - 21 consecutive days16,17,23. Because the minimum 
cytotoxic concentrations depend not only on the tumour cell type but also 
on the incubation time, we designed an in vitro study which was supposed 
to simulate the incubation time and concentration-time profiles of the in 
vivo situation. The EC
50
 values of etoposide reflecting growth inhibition of 
medulloblastoma cells (D-425med) by 50 % after five days of incubation 
was 0.20 µg/mL in our study. The C
min
 values after all dosage regimens of 
etoposide were close to or above this concentration. Comparing the mean 
C
max 
and
 
C
min 
values with the EC
50
 values from our in vitro studies, it can be 
assumed that all three dosage regimens lead to concentrations of 
etoposide in the CSF that are sufficiently high to achieve antitumour 
activity.   
5.2.2 Distribution of etoposide in the CSF  
The t
1/2λ1 in CSF ranged from 0.63 to 0.72 h indicating rapid distribution of 
etoposide in the CSF. Moreover, etoposide seems to equilibrate well in the 
CSF compartment after ivc administration because there was no difference 
in etoposide concentration between samples obtained from the OMR and 
by lumbar puncture four hours after ivc administration. Drugs which are 
administered through the OMR are carried in the same direction as the CSF 
bulk flow44. This might be a reason for the good distribution of etoposide 
in the CSF compartment after ivc administration. However, the small V
ss
 of 
etoposide (about 150 mL) indicates that etoposide distributes mainly 
inside the CSF compartment which exhibits a total volume between 80 and 
150 mL89. This result is in agreement with Blasberg et al.90 who reported 
that after intrathecal drug therapy of hydroxyurea, methotrexate, thiotepa, 
1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and cytarabine in the rhesus 
monkey, drug diffusion was limited. The drugs only differed into brain 
parenchyma or subarachnoid tumour nodules by 2 - 3 mm. Basically, the 
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distribution of drugs from the intrathecal space depends on the 
physicochemical properties of the drug and the unbound fraction. 
Lipophilic drugs readily enter the spinal cord where they are absorbed 
systemically, whereas hydrophilic drugs tend to remain in the CSF. 
However, only the lipid-soluble molecules with a molecular weight lower 
than 500 Dalton can pass across the BBB88. Molecular weight of etoposide 
is greater than 500 Dalton. This might be one possible reason why 
etoposide is mostly distributed in the CSF compartment, even though 
etoposide is a lipophilic drug and exhibits low protein binding in CSF.  
5.2.3 Elimination of etoposide from the CSF 
The t
1/2z
 of etoposide in CSF ranged from 6.76 to 7.15 h indicating that 
etoposide is slowly eliminated from the CSF. Normally, drug clearance 
from the CSF can occur by CSF bulk flow to the arachnoid villi of the 
superior sagittal sinus and spinal epidural veins, active transport at the 
choroid plexus and extrachoroidal sites, diffusion into the central nervous 
system extracellular fluid and capillaries, and uptake or metabolism by 
central nervous system cells91. CSF bulk flow is usually of 0.30 – 
0.52 mL/min92 which is comparable to the mean CL of etoposide from CSF 
of 0.33 - 0.45 mL/min. Therefore, it is likely that etoposide is eliminated 
mainly through CSF bulk flow. The variability of t
1/2z 
and
 
CL might be 
explained by the different ability to produce and excrete CSF as well as 
different CSF volumes among the patients. Our results showed no 
etoposide accumulation after repeated administration of etoposide on five 
consecutive days. Therefore, the risk of reaching potentially toxic 
concentrations is low.   
5.2.4 Effect of disease state 
The large variability of pharmacokinetic parameters of etoposide that we 
observed after all studied dosing regimens might be a consequence of the 
disease state of the patient, differences in individual CSF volume or 
different production, and excretion rate of the CSF. The effect of a 
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hydrocephalus on the pharmacokinetic disposition of etoposide in CSF was 
monitored in three cycles of one patient at the age of 0.92 years. This 
patient suffered from a medulloblastoma with leptomeningeal metastases. 
This tumour was resistant to first-line therapy, complicated by a 
hydrocephalus occlusus and the necessity of a ventricular-peritoneal shunt. 
Comparing the V
ss
 in this patient to the V
SS
 of the other two patients who 
received etoposide in the same dosage regimen, the V
ss
 of this patient was 
larger than those found in the other two patients. Therefore, it can be 
assumed that the large V
ss
 in this patient was the effect of the 
hydrocephalus. The C
max
 of this patient was considerably lower compared 
to the C
max
 values of the other two patients due to the larger V
ss
.  
5.2.5 Comparison with other intra-CSF administered agents 
At present, methotrexate, cytarabine and thiotepa are widely used for 
intra-CSF therapy. Other cytotoxic agents such as mafosfamide, topotecan, 
diaziquone, temozolomide and etoposide have been studied for intra-CSF 
therapy. Tab. 27 summarises the pharmacokinetic parameters of these 
agents in CSF after intra-CSF administration available so far. Nimustine, 
mercaptopurine, mafosfamide, and diaziquone exhibit very short half-lives 
whereas topotecan, cytarabine, etoposide, and methotrexate show longer 
half-lives between 3 – 13 hours. The longest half-life was reported for 
liposomal cytarabine.  
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Table 27. Pharmacokinetic parameters of anticancer agents in CSF after 
intra-CSF administration  
* = Data from our study; Adm. = Administration; n.a. = not available; pts. = patients 
 
 
Agent 
Dose 
[mg] 
Adm. 
No. 
of 
pts. 
CL 
[mL/min] 
V
ss
 
[L] 
t
½z
 
[h] 
Nimustine93 10-20 ivc 3 n.a. n.a. 0.2-1.1 
Diaziquone52 1, 2 ivc 6 
0.37 
(0.10-0.93) 
n.a. 
1.3 
(0.8-2.6) 
Mercaptopurine45 5, 10 ivc 7 0.63 n.a. 1.4 
Mafosfamide58 1-5 ivc, LP 11 
0.50 
(0.19-1.10) 
n.a. 
1.2 
(0.7–2.6) 
Topotecan54 0.2-0.7 ivc, LP 9 
0.3 
(0.23-0.35) 
0.04-0.05 
2.6 
(2.4-2.9) 
30 ivc 7 n.a. 0.55 
3.4 
(2.5-4.4) 
Cytarabine45,93 
15-30 Ivc 3 n.a. n.a. (1.8-6.2) 
Etoposide* 0.5-1 ivc 22 0.33-0.45 0.11-0.16 6.8-7.2 
10-20 ivc 3 n.a. n.a. 2.2-13.5 
0.5 ivc 1 n.a. n.a. 6.6 
6.25 
mg/m2 
ivc 5 n.a. n.a. 8 
6 ivc 12 n.a. 0.03 
5.7 
(3.3-20) 
12 
mg/m2 
ivc 16 n.a. n.a. 7.1 
Methotrexate45,93 
15 
mg/m2 
ivc n.a. n.a. n.a. 10.5 
Liposomal 
Cytarabine55 
50 ivc, LP 2 n.a. n.a. 55-57 
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5.2.6 Clinical consequences 
The pharmacokinetic data of intraventricularly administered etoposide 
displayed dose-independent pharmacokinetics in the CSF. The AUC 
increases proportionally with dose indicating linear pharmacokinetics. 
Linear pharmacokinetics is an important prerequisite for the safe use of 
this new mode of administration.  
Intraventricular chemotherapy is primarily directed against cells dispersed 
within or lining the CSF compartment rather than against malignant cells 
within the brain parenchyma. Main factors for its consideration are the 
distribution of the drug within the CSF, the extent of drug clearance from 
the CSF and the time course of action94. Considering these factors along 
with our pharmacokinetic data, ivc etoposide seem to be suitable for 
treating tumours or metastases which are located in or close to the CSF 
space to prevent further seeding into the leptomeninges.  
Moreover, our data might be used to simulate concentration-time profiles 
following other regimens in order to optimise ivc therapy of etoposide. A 
prospective, randomized multi-institutional phase II clinical trial of 
intraventricularly administered etoposide is currently conducted to assess 
the clinical response and the quality of life.  
5.3 In vitro pharmacodynamics of etoposide in 
medulloblastoma cells 
Conventionally, in in vitro experiments the tumour cells are exposed to 
constant concentrations of cytotoxic agents. In fact, in the in vivo situation 
the tumour cells are not exposed to constant concentrations but to a 
specific concentration-time profile which is determined by pharmacokinetic 
processes. One aim of our in vitro experiments was to study the effect of 
the dosage regimen on medulloblastoma cells. The concentration-time 
profiles were simulated using data from the clinical study.  
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5.3.1 Suitability of the colony forming assay  
The colony forming assay was used to determine the effect of 
concentration, duration of exposure and dosage regimen on etoposide 
antiproliferative activity. The colony forming assay is a direct measure of 
cell survival and proliferation. It is a reproducible method, easy to set up, 
and inexpensive. Moreover, the colony forming assay can be used to 
measure the antiproliferative activity without ”dead-cell condition” which is 
needed in the MTT test. Disadvantages are that it is time-consuming and 
labour-intensive. Usually, the stepwise dilution can lead to cell loss and 
reduce the number of colony forming units especially when cells are 
suspended in culture medium. Thus, it can interfere with the measured 
antiproliferative effect caused by etoposide. However, in our study tumour 
cells were fixed to the surface of the culture plate. Therefore, the 
probability to lose tumour cells along with the dilution step is low 
compared to the suspension model. A limitation of our experimental 
conditions is that the form of the cells differs from the form under in vivo 
conditions where cells are in spheroid form (solid tumour) or floating in 
the CSF compartment95,96.  
5.3.2 Effect of concentration and duration of exposure on 
antiproliferative activity  
The results obtained in this study demonstrated that the antiproliferative 
activity of etoposide on medulloblastoma cells depends on concentration 
and duration of exposure of the drug. This observation is in agreement 
with previous reports13,18-22. The concentration-dependence of 
antiproliferative activity of etoposide would support the concept of high-
dose therapy which maximises total drug exposure. However, this strategy 
would produce more systemic toxicity such as myelosuppression which is 
the dose-limiting toxicity of etoposide. At the same time, our results 
showed that the etoposide antiproliferative activity also depends on the 
duration of exposure. As the duration of exposure increases, the dose 
required to produce maximum antiproliferative activity decreases. Our 
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results are in accordance with in vivo studies which showed the advantage 
of schedules with longer drug exposure in tumour patients16,17,23. The 
clinical trial from Slevin et al.16 showed that the response rate of etoposide 
100 mg/m2 given on five consecutive days is clearly superior to the 
response rate of etoposide 500 mg/m2 administered as 24 h continuous 
infusion. Both in vitro and in vivo results support and confirm the benefit 
of a prolonged therapy regimen which offers a therapeutic advantage in 
terms of both efficacy and toxicity. In vitro results from Liu et al.13 also 
showed that at the same total drug exposure, etoposide cytotoxic activity 
increased relatively with duration of exposure. He recognised also the 
importance of etoposide concentration. If etoposide concentration was 
below an effective threshold, the cytotoxic activity in schedules of more 
protracted duration showed a gradual reduction. Therefore, it is necessary 
to find out the suitable duration of exposure and the sufficient total drug 
exposure or the threshold of etoposide concentration for each type of 
tumour cell.  
5.3.3 Effect of dosage regimen  
One of the objectives of this study was to investigate the effect of dosage 
regimen on the antiproliferative activity of etoposide. The results show 
that a twice daily regimen of etoposide exhibits a higher antiproliferative 
activity than a once daily regimen. In the pharmacokinetic study in brain 
tumour patients both dosage regimens (0.25 mg/12 h and 0.50 mg/24 h) 
led to a comparable total drug exposure, but after the twice daily regimen 
drug concentration was longer above the EC
50
 than after the once daily 
regimen. From the in vitro experiments it can be concluded that prolonged 
maintenance of low etoposide concentrations is more important for 
obtaining a response than high peak concentrations. This supports the so 
called concentration times time (C x T) strategy, i.e. repeating low doses of 
etoposide over a relatively short period of time.  
An explanation of these experimental observations is that etoposide is 
classified as cell cycle phase-specific cytotoxic agent. Main target of 
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etoposide is DNA topoisomerase II. It induces the formation of DNA 
topoisomerase II cleavable complexes which results in DNA single- and 
double- strand breaks. This action takes place in two specific phases. The 
first one is the phase between the last division and the start of DNA 
replication (the S phase) and the second phase is the replication of DNA 
(the G
2
 phase)1. The effect of etoposide on the DNA topoisomerase II 
complex is reversible when the cells have been incubated with 
inappropriate time or insufficient concentrations which may be non- or 
sub-lethal to the cells. This means that a longer exposure to a threshold 
concentration of etoposide would affect more cells as a larger fraction of 
cells completes a full cell cycle.  
In conclusion, etoposide 0.25 mg/12 h may be the best dosage regimen of 
the regimens studied because of a higher antiproliferative efficacy. 
Moreover, toxicity is probably comparable to the regimen 0.50 mg/24 h 
because of a similar drug exposure. These findings should be confirmed in 
a randomised, controlled clinical trial.  
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6. Summary 
Intraventricular (ivc) administration of etoposide was introduced to solve 
one of the major problems in treating central nervous system tumours, 
namely the limited distribution of cytotoxic drugs across the blood-brain 
barrier. Well characterised relationships between pharmacokinetics and 
pharmacodynamics facilitate the clinical development of optimal dosage 
regimens. 
Pharmacokinetic disposition of etoposide in cerebrospinal fluid was 
investigated in 22 patients (119 cycles) after intraventricular 
administration of three different dosage regimens (0.25 mg/12 h, 
0.5 mg/24 h and 1.0 mg/24 h) through an Ommaya reservoir. CSF 
concentrations of etoposide were determined by reversed-phase high-
performance liquid chromatography (HPLC) with electrochemical detection. 
The pharmacokinetic parameters were estimated by using a two-
compartment model and Bayesian curve fitting. The maximum 
concentration (C
max
) of etoposide in CSF was observed 15 minutes after ivc 
administration. Mean C
max
 and area under the curve of etoposide in CSF 
increased proportionally with etoposide dose. After repeated ivc 
administration of etoposide on five consecutive days no drug accumulation 
in CSF was observed. The pharmacokinetics of etoposide in the CSF was 
found to be dose- and schedule-independent in the dose range studied as 
no statistically significant differences were found in terminal elimination 
half-life (t
1/2z
), volume of distribution (V
ss
) and clearance (CL) among the 
three dosage regimens. One patient with a hydrocephalus exhibited a 
larger V
ss
. The distribution of etoposide inside the CSF compartment was 
investigated by simultaneous collection of CSF samples via Ommaya 
reservoir (OMR) and lumbar puncture (LP) four hours after an ivc 
administration. Etoposide concentrations did not differ between both sites 
indicating homogeneous distribution of etoposide in the CSF after ivc 
administration.  
In order to characterise the pharmacodynamics of etoposide in 
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medulloblastoma cells, the effect of concentration and total drug exposure 
on antiproliferative activity was investigated in D-425med cells by using 
the colony forming assay. The cells were incubated with different 
etoposide concentrations but the total drug exposures (AUC, concentration 
x duration of exposure) were kept constant. The percent colonies 
remaining decreased when etoposide concentration was increased. The 
EC
50
 of etoposide after an incubation time of 12 h was around two times 
higher than that obtained after the incubation times 24 h and 120 h. 
However, the AUC
50
 (duration x concentration) was comparable among the 
three groups. The results indicate that the antiproliferative activity of 
etoposide on medulloblastoma cells mainly depends on total drug 
exposure. Moreover, the effects of two different dosing schedules (once 
daily and twice daily on five consecutive days) on the medulloblastoma 
cells were investigated by using an in vitro dilution model. At the same 
total exposure, fewer colonies remained after exposure with simulated 
concentration-time profiles of etoposide given every 12 h compared to the 
regimen with etoposide administration every 24 h. The in vitro 
pharmacodynamic investigation revealed that at the same drug exposure 
(AUC), the twice daily administration was more effective than the once 
daily administration.  
In conclusion, the clinical results indicate linear pharmacokinetics of 
intraventricularly administered etoposide in the CSF which is an important 
prerequisite for the safe use of this new mode of administration. The in 
vitro results suggest that a more frequent administration of etoposide is 
favourable as it can produce a higher antiproliferative activity with the 
same drug exposure. 
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Appendix A 
A1: Patient characteristics  
A2: Individual concentration-time profiles of patients which were used to 
generate population parameters. 
A3: Individual etoposide pharmacokinetic parameters for each cycle  
 
Appendix B 
B1: Individual data of the MTT assay  
B2: Individual data of the colony forming assay (effect of concentration and 
duration of exposure) 
B3: Simulated concentration-time profiles of etoposide (0.25 mg/12 h and 
0.50 mg/24 h) derived by compartmental data analysis using W = 1/y2 
B4: Individual data of the colony forming assay (effect of dosage regimen) 
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Characteristics of patients (0.25 mg/12 h) 
Pt G 
No. of 
cycles 
Age 
[years] 
W 
[kg] 
H 
[cm] 
BSA 
[m2] 
Diagnosis 
1 F 4 18 68 162 1.70 
2nd relapse of 
medulloblastoma and spinal 
metastases 
2 M 1 4 15 96 0.65 
1st relapse of acute 
lymphoblastic leukaemia 
with CNS manifestation 
3 F 3 0.92 13 72 0.51 
Medulloblastoma with 
leptomeningeal metastases, 
resistant to first-line 
therapy, complicated by 
hydrocephalus occlusus and 
need of a ventricular-
peritoneal shunt  
Pt = patient, G = gender, W = weight, H = height, BSA = body surface area 
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Characteristics of patients (0.5 mg/24 h) 
Pt G 
No. of 
cycles 
Age 
[years] 
W 
[kg] 
H 
[cm] 
BSA 
[m2] 
Diagnosis 
1 F 5 18 68 162 1.70 
2nd relapse of medulloblas-
toma and spinal metastases 
4 M 1 11 33 143 1.13 
Malignant ependymoma, 3rd 
cervical spinal local relapse 
5 F 1 32 77 153 1.83 
1st relapse of medulloblas-
toma of fossa posterior and 
three cerebral metastases 
6 F 12 3 10 89 0.50 
Pineoblastoma with menin-
geal metastases, residual 
tumour in cauda equina 
after first-line therapy 
7 F 2 21 50 168 1.54 
Intraspinal malignant peri-
pheral nerve sheath tumour 
with meningeal metastases 
8 M 2 7 29 118 0.96 
Relapse of medulloblastoma 
with leptomeningeal 
metastases, cluster of tumor 
cells in the ventricular und 
lumbar CSF 
9 F 8 25 61 173 1.72 
3rd relapse of medulloblas-
toma of fossa posterior with 
spinal thoracal metastases 
10 M 6 15 46 178 1.56 
Relapse of medulloblastoma 
locally and in the 4th 
ventricle, bone metastases 
Pt = patient, G = gender, W = weight, H = height, BSA = body surface area 
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Characteristics of patients (1.0 mg/24 h) 
Pt G 
No. of 
cycles 
Age 
[years] 
W 
[kg] 
H 
[cm] 
BSA 
[m2] 
Diagnosis 
1 F 6 18 68 162 1.70 
2nd relapse of medulloblas-
toma with spinal metastases 
11 M 6 31 76 180 1.95 
2nd local relapse of medullo-
blastoma with spinal 
metastases 
12 M 1 12 n.a. n.a. n.a. 
1st relapse of desmoplastic 
medulloblastoma 
13 M 27 6 27 114 0.92 
1st relapse of medulloblas-
toma with spinal metastases 
14 M 4 7 22 120 0.86 
1st relapse of anaplastic 
ependymoma 
15 F 3 10 32 125 1.05 
Multiple relapse of plexus 
carcinoma 
16 M 1 19 55 172 1.62 
PNET in pineal region, 2nd 
local relapse with meninge-
osis, CSF with tumour cells  
17 F 2 7 36 137 1.17 
1st relapse of medulloblas-
toma with three lesions in 
the right lateral ventricle, 
CSF with tumour cells  
18 M 1 5 14 101 0.64 
1st local relapse of medullo-
blastoma, residual tumour in 
the 4th ventricle 
19 F 2 3 n.a. n.a. n.a. 
1st spinal relapse of medullo-
blastoma 
Pt = patient, G = gender, W = weight, H = height, BSA = body surface area, 
n.a. = not available 
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Characteristics of patients (1.0 mg/24 h, continued) 
Pt G 
No. of 
cycles
 
Age 
[years]
 
W 
[kg] 
H 
[cm]
 
BSA 
[m2] 
Diagnosis 
20 F 3 13 58 164 1.62 
Medulloblastoma, resistant 
to first-line therapy, 
metastases in the 3rd 
ventricle, ventricular CSF 
with tumour cells 
21 F 6 5 n.a. n.a. n.a. 
Medulloblastoma, residual 
vital tumour after first-line 
therapy  
22 M 2 10 n.a. n.a. n.a. 
1st relapse of medulloblas-
toma with meningeosis 
23 M 9 12 35 141 1.17 
1st relapse of 
medulloblastoma, meta-
stases in the cerebellum, 
meningeosis, spinal 
metastases 
Pt = patient, G = gender, W = weight, H = height, BSA = body surface area, 
n.a. = not available 
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Appendix A2 
Individual concentration-time profiles of patients 
which were used to generate population parameters 
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CSF concentration-time profile of patient 1 (cycle 9) following ivc 
administration of etoposide 1 mg/24 h 
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CSF concentration-time profile of patient 4 (cycle 1) following ivc 
administration of etoposide 0.5 mg/24 h 
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CSF concentration-time profile of patient 5 (cycle 1) following ivc 
administration of etoposide 0.5 mg/24 h 
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CSF concentration-time profile of patient 8 (cycle 1) following ivc 
administration of etoposide 0.5 mg/24 h 
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CSF concentration-time profile of patient 9 (cycle 1) following ivc 
administration of etoposide 0.5 mg/24 h 
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CSF concentration-time profile of patient 11 (cycle 1) following ivc 
administration of etoposide 1 mg/24 h 
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CSF concentration-time profile of patient 15 (cycle 1) following ivc 
administration of etoposide 1 mg/24 h 
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Appendix A3 
Individual etoposide pharmacokinetic parameters for each cycle 
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Individual etoposide pharmacokinetic parameters in each cycle 
(0.25 mg/12 h)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
1 3 124.87 0.33 0.08 0.13 5.24 0.81 6.52 
1 4 110.21 0.38 0.12 0.20 5.63 0.68 6.61 
1 5 112.97 0.37 0.09 0.15 7.65 0.80 6.50 
1 C 113.13 0.37 0.11 0.18 6.07 0.68 6.60 
2 1 139.70 0.30 0.13 0.37 3.61 0.54 7.21 
3 1 64.13 0.65 0.45 0.43 0.99 0.39 9.39 
3 2 87.72 0.48 0.18 0.20 0.24 0.60 6.96 
3 3 182.51 0.23 0.09 0.49 0.94 0.61 7.16 
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Individual etoposide pharmacokinetic parameters in each cycle 
(0.5 mg/24 h)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
1 1 96.57 0.43 0.13 0.08 10.33 0.66 6.58 
1 2 121.20 0.34 0.12 0.13 9.85 0.78 6.82 
1 7 78.64 0.53 0.18 0.08 7.37 0.63 6.73 
1 A 153.49 0.27 0.09 0.13 13.69 0.67 6.65 
1 B 148.67 0.28 0.10 0.15 10.64 0.78 6.83 
4 1 54.03 0.77 0.18 0.02 3.08 0.81 6.47 
5 1 34.11 1.22 0.38 0.03 2.56 0.47 6.64 
6 1 187.35 0.22 0.07 0.05 17.40 0.67 6.56 
6 2 158.35 0.26 0.04 0.05 18.55 0.76 6.46 
6 3 210.25 0.20 0.06 0.04 19.83 0.67 6.53 
6 4 137.12 0.30 0.10 0.08 12.05 0.67 6.61 
6 5 193.70 0.22 0.06 0.06 17.59 0.68 6.53 
6 6 175.30 0.24 0.08 0.05 13.24 0.67 6.62 
6 9 255.91 0.16 0.02 0.06 43.83 0.46 6.52 
6 10 481.42 0.09 0.02 0.25 55.98 0.68 6.39 
6 11 372.31 0.11 0.03 0.11 31.88 0.67 6.51 
6 12 497.89 0.08 0.02 0.16 53.01 0.67 6.40 
6 13 234.59 0.18 0.06 0.15 20.42 0.66 6.59 
6 14 358.17 0.12 0.03 0.12 31.40 0.67 6.47 
6 15 197.42 0.21 0.06 0.06 17.90 0.67 6.55 
6 16 443.56 0.09 0.03 0.17 45.23 0.67 6.43 
6 17 160.19 0.26 0.08 0.09 14.57 0.68 6.56 
6 18 69.98 0.60 0.20 0.09 n.a. 0.63 6.72 
7 1 182.27 0.23 0.07 0.06 17.14 0.68 6.53 
7 2 132.79 0.31 0.07 0.07 17.34 0.70 6.40 
8 1 201.07 0.21 0.09 0.26 11.89 0.91 7.17 
8 2 140.86 0.30 0.11 0.15 7.41 0.67 6.74 
n.a. = not available 
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Individual etoposide pharmacokinetic parameters in each cycle 
(0.5 mg/24 h, continued)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
9 1 152.60 0.27 0.09 0.11 n.a. 1.70 6.49 
9 2 150.93 0.28 0.09 0.15 n.a. 0.78 6.74 
9 3 106.34 0.39 0.19 n.a. 5.54 1.42 9.98 
9 4 145.07 0.29 0.13 0.20 7.05 1.19 7.68 
9 5 143.03 0.29 0.13 0.18 7.51 1.15 7.45 
9 6 120.72 0.35 0.16 0.18 5.65 0.71 7.32 
9 7 181.27 0.23 0.09 0.19 11.67 0.49 6.04 
9 8 146.45 0.29 0.11 0.22 12.24 0.45 6.22 
10 4 198.69 0.21 0.07 n.a. 17.36 0.66 6.74 
10 5 224.32 0.19 0.06 n.a. 19.64 0.66 6.67 
10 6 136.90 0.31 0.11 0.24 10.59 0.64 6.92 
10 7 268.42 0.16 0.08 0.24 18.36 0.62 8.66 
10 8 208.96 0.20 0.06 0.12 19.23 0.67 6.58 
10 9 141.51 0.30 0.09 0.05 13.24 0.67 6.58 
n.a. = not available 
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Individual etoposide pharmacokinetic parameters in each cycle 
(1.0 mg/24 h)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
1 6 206.63 0.40 0.12 0.13 22.08 0.63 6.59 
1 8 95.17 0.88 0.27 0.08 12.17 0.60 6.50 
1 9 284.20 0.29 0.07 0.08 18.87 0.79 6.07 
1 10 227.64 0.37 0.12 0.20 17.82 0.71 6.62 
1 11 258.95 0.32 0.10 0.18 24.10 0.67 6.61 
1 12 123.48 0.68 0.22 0.11 15.44 0.60 6.53 
11 1 159.88 0.52 0.11 0.08 21.52 0.81 7.48 
11 2 207.19 0.40 0.12 0.25 31.68 0.52 7.65 
11 3 203.01 0.41 0.12 0.23 18.95 0.67 6.66 
11 4 105.08 0.79 0.21 0.07 16.14 0.64 6.48 
11 5 177.19 0.47 0.14 0.15 48.84 0.72 6.53 
11 6 205.24 0.41 0.11 0.11 27.41 0.69 6.46 
12 1 286.98 0.29 0.11 0.25 23.46 0.67 7.00 
13 1 233.30 0.36 0.12 0.25 20.03 0.65 6.73 
13 2 161.96 0.52 0.16 0.07 14.66 0.66 6.58 
13 3 161.26 0.52 0.17 0.13 14.12 0.65 6.64 
13 4 156.59 0.53 0.17 0.10 14.14 0.65 6.61 
13 5 252.53 0.33 0.11 0.24 20.92 0.65 6.73 
13 6 130.26 0.64 0.18 0.10 14.64 0.64 6.49 
13 7 133.90 0.62 0.20 0.08 12.16 0.64 6.59 
13 8 188.26 0.44 0.14 0.08 17.23 0.67 6.56 
13 9 153.93 0.54 0.17 0.12 13.71 0.65 6.59 
13 10 256.55 0.33 0.10 0.16 23.18 0.68 6.57 
13 11 144.84 0.58 0.19 0.11 13.10 0.64 6.63 
13 12 187.22 0.45 0.14 0.13 17.13 0.67 6.57 
13 13 208.74 0.40 0.15 0.29 16.03 0.63 6.90 
13 14 309.08 0.27 0.09 0.21 26.51 0.67 6.62 
n.a. = not available 
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Individual etoposide pharmacokinetic parameters in each cycle 
(1.0 mg/24 h, continued)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
13 15 256.77 0.33 0.09 0.11 24.05 0.69 6.48 
13 16 266.39 0.31 0.09 0.18 24.78 0.68 6.55 
13 17 217.52 0.38 0.12 0.16 19.70 0.67 6.56 
13 18 251.72 0.33 0.10 0.20 22.63 0.67 6.60 
13 19 256.73 0.33 0.10 0.14 22.73 0.67 6.59 
13 20 333.98 0.25 0.08 0.24 30.88 0.68 6.55 
13 21 226.72 0.37 0.11 0.13 20.67 0.68 6.54 
13 22 192.63 0.43 0.14 1.49 20.00 0.66 6.61 
13 23 116.85 0.71 0.23 0.09 10.67 0.62 6.62 
13 24 146.67 0.57 0.18 0.11 13.34 0.65 6.60 
13 25 154.83 0.54 0.19 0.16 16.59 0.65 6.82 
13 26 166.41 0.50 0.17 0.16 14.59 0.65 6.67 
13 27 187.08 0.45 0.14 0.10 16.86 0.66 6.61 
14 1 456.92 0.18 0.13 1.71 22.71 0.49 9.66 
14 2 678.44 0.12 0.10 0.72 25.54 0.45 10.95 
14 3 483.63 0.17 0.12 1.71 23.53 0.51 9.87 
14 4 443.15 0.19 0.14 1.50 20.73 0.51 10.02 
15 1 345.47 0.24 0.10 0.52 25.61 0.62 7.08 
15 2 244.03 0.34 0.20 0.81 13.13 0.53 8.68 
15 3 161.11 0.52 0.30 0.66 8.59 0.50 8.46 
16 1 160.99 0.52 0.12 0.06 21.44 0.64 6.39 
17 1 207.02 0.40 0.16 0.23 13.27 0.69 7.08 
17 2 196.80 0.42 0.17 0.18 12.26 0.65 7.01 
18 1 118.72 0.70 0.22 0.03 n.a. 0.63 6.58 
19 1 188.00 0.44 0.14 0.04 16.77 0.67 6.60 
19 2 122.83 0.68 0.22 0.04 n.a. 0.63 6.61 
20 1 166.91 0.50 0.16 0.07 14.78 0.66 6.59 
n.a. = not available 
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Individual etoposide pharmacokinetic parameters in each cycle 
(1.0 mg/24 h, continued)  
Pt 
No. of 
cycles 
AUC
total
  
[µg x h/mL] 
CL 
[mL/min] 
V
ss
 
[L] 
C
min
 
[µg/mL] 
C
max
 
[µg/mL] 
t
1/2λ1 
[h-1] 
t
1/2z
 
[h-1] 
20 2 172.50 0.48 0.11 0.08 15.63 0.97 6.31 
20 3 90.51 0.92 0.27 0.07 n.a. 0.63 6.23 
21 1 119.12 0.70 0.22 0.07 10.97 0.62 6.60 
21 2 135.30 0.62 0.20 0.10 12.23 0.64 6.62 
21 3 79.41 1.05 0.38 0.09 6.15 0.52 6.73 
21 4 91.61 0.91 0.33 0.13 7.58 0.55 6.77 
21 5 238.54 0.35 0.11 0.09 21.72 0.68 6.56 
21 6 219.62 0.38 0.11 0.07 20.98 0.68 6.51 
22 1 236.17 0.35 0.13 0.36 18.69 0.64 6.87 
22 2 194.40 0.43 0.16 0.31 15.09 0.62 6.96 
23 1 573.85 0.15 0.12 2.50 22.97 0.47 10.90 
23 2 264.87 0.32 0.17 0.62 16.30 0.55 8.13 
23 3 184.92 0.45 0.15 0.17 16.21 0.66 6.66 
23 4 541.75 0.15 0.11 1.74 23.62 0.48 10.00 
23 5 193.46 0.43 0.14 0.22 20.46 0.66 6.46 
23 6 371.02 0.23 0.13 1.17 20.01 0.54 8.71 
23 7 441.21 0.19 0.12 1.15 23.63 0.53 8.93 
23 8 274.78 0.30 0.11 0.27 22.52 0.65 6.84 
23 9 402.54 0.21 0.13 1.49 20.00 0.53 9.19 
n.a. = not available 
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Appendix B1 
Individual data of the MTT assay 
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Individual data of the MTT assay 
 Absorption 
Etoposide 
Conc. [M] 
10-9 10-8 10-7 10-6 10-5 10-4.5 10-4 10-3.75 
1 1.27 1.47 1.30 0.41 0.09 0.11 0.16 0.15 
2 1.15 1.41 1.31 0.29 0.14 0.12 0.14 0.14 
3 1.32 1.11 1.11 0.44 0.13 0.11 0.13 0.18 
4 1.41 1.42 1.21 0.46 0.14 0.16 0.13 0.15 
5 1.41 1.24 1.15 0.44 0.17 0.12 0.14 0.15 
6 1.37 1.28 1.19 0.37 0.17 0.11 0.13 0.14 
7 1.45 1.31 1.09 0.38 0.13 0.07 0.11 0.14 
8 1.39 * 1.20 0.48 0.14 0.11 0.12 0.14 
9 1.44 1.13 1.08 0.41 0.14 0.12 0.12 0.14 
10 1.29 1.10 * 0.33 0.15 0.10 0.10 0.17 
11 1.40 1.17 1.13 0.33 0.12 0.11 0.13 0.14 
12 1.21 1.21 1.19 0.38 0.15 0.11 0.15 0.14 
         
Mean 1.34 1.26 1.18 0.39 0.14 0.11 0.13 0.15 
SD 0.10 0.13 0.08 0.06 0.02 0.02 0.02 0.01 
* Data were excluded because they were much different from other values 
and hence regarded as outliers. 
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Appendix B2 
Individual data of the colony forming assay  
(effect of concentration and duration of exposure) 
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Number of colonies remaining of D-425med incubated with etoposide for 
12 h 
Etoposide Conc.  No. of colonies remaining Mean 
(M) 1 2 3  
2 x 10-8.0 187 256 192 211.67 
2 x 10-7.0 219 194 247 220.00 
2 x 10-6.8  129 148 155 144.00 
2 x 10-6.75 164 197 183 181.33 
2 x 10-6.65 103 148 178 143.00 
2 x 10-6.4 101 148 146 131.67 
2 x 10-6.25 40 43 27 36.67 
2 x 10-6.1 26 19 25 23.33 
2 x 10-6.0 17 9 16 14.00 
2 x 10-5.0 0 0 0 0 
 
 
Percent colonies remaining of D-425med incubated with etoposide for 12 h 
Etoposide Conc.  % colonies remaining Mean 
(M) 1 2 3  
2 x 10-8.0 100.00 100.00 100.00 100.00 
2 x 10-7.0 103.46 91.65 116.69 103.94 
2 x 10-6.8  60.94 69.92 73.23 68.03 
2 x 10-6.75 77.48 93.07 86.46 85.67 
2 x 10-6.65 48.66 69.92 84.09 67.56 
2 x 10-6.4 47.72 69.92 68.98 62.20 
2 x 10-6.25 18.90 20.31 12.76 17.32 
2 x 10-6.1 12.28 8.98 11.81 11.20 
2 x 10-6.0 8.03 4.25 7.56 6.61 
2 x 10-5.0 0.00 0.00 0.00 0.00 
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Number of colonies remaining of D-425med incubated with etoposide for 
24 h 
Etoposide Conc.  No. of colonies remaining Mean 
(M) 1 2 3  
10-8.0 191 252 247 230.00 
10-7.0 253 259 n.a. 256.00 
10-6.8  224 274 168 222.00 
10-6.75 265 208 197 223.33 
10-6.65 118 169 163 150.00 
10-6.4 187 139 121 149.00 
10-6.25 68 53 53 58.00 
10-6.1 37 38 22 32.33 
10-6.0 11 10 2 7.67 
10-5.0 0 0 0 0.00 
n.a. = not available 
 
Percent colonies remaining of D-425med incubated with etoposide for 24 h 
Etoposide Conc.  % colonies remaining Mean 
(M) 1 2 3  
10-8.0 100.00 100.00 100.00 100.00 
10-7.0 110.00 112.61 n.a. 111.30 
10-6.8  97.39 119.13 73.04 96.52 
10-6.75 115.22 90.43 85.65 97.10 
10-6.65 51.30 73.48 70.87 65.22 
10-6.4 81.30 60.43 52.61 64.78 
10-6.25 29.57 23.04 23.04 25.22 
10-6.1 16.09 16.52 9.57 14.06 
10-6.0 4.78 4.35 0.87 3.33 
10-5.0 0.00 0.00 0.00 0.00 
 
 
 
Appendix 128 
 
Number of colonies remaining of D-425med incubated with etoposide for 
120 h 
Etoposide Conc.  No. of colonies remaining Mean 
(M) 1 2 3  
1/5 x 10-8.0 267 296 365 309.33 
1/5 x 10-7.0 342 287 317 315.33 
1/5 x 10-6.8  174 248 240 220.67 
1/5 x 10-6.75 289 183 182 218.00 
1/5 x 10-6.65 230 131 205 188.67 
1/5 x 10-6.4 181 168 217 188.67 
1/5 x 10-6.25 48 91 83 74.00 
1/5 x 10-6.1 77 50 89 72.00 
1/5 x 10-6.0 21 20 31 24.00 
1/5 x 10-5.0 0 0 0 0.00 
 
 
Percent colonies remaining of D-425med incubated with etoposide for 
120 h 
Etoposide Conc.  % colonies remaining Mean 
(M) 1 2 3  
1/5 x 10-8.0 100.00 100.00 100.00 100.00 
1/5 x 10-7.0 110.56 92.78 102.48 101.94 
1/5 x 10-6.8  56.25 80.17 77.59 71.34 
1/5 x 10-6.75 93.43 59.16 58.84 70.47 
1/5 x 10-6.65 74.35 42.35 66.27 60.99 
1/5 x 10-6.4 58.51 54.31 70.15 60.99 
1/5 x 10-6.25 15.52 29.42 26.83 23.92 
1/5 x 10-6.1 24.89 16.16 28.77 23.28 
1/5 x 10-6.0 6.79 6.47 10.02 7.76 
1/5 x 10-5.0 0.00 0.00 0.00 0.00 
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Appendix B3 
Simulated concentration-time profiles of etoposide  
(0.25 mg/12 h and 0.50 mg/24 h)  
derived by compartmental data analysis using W = 1/y2 
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Simulated concentration-time profile of etoposide administered every 12 h 
with 15-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 1260 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 252 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 804 ng/mL to obtain an etoposide 
concentration of 252 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 251.92 - - 252.00 
0.25 - 0.50 225.68 522.32 522 225.69 
0.50 - 1.00 164.33 1359.32 1350 164.75 
1.00 - 2.00 96.83 2061.50 2050 97.21 
2.00 - 4.00 48.00 2530.94 2550 47.63 
4.00 - 8.00 25.22 2352.80 2350 25.24 
8.00 - 12.00 15.64 1902.26 1900 15.65 
Only for day 6 
0.00 - 12.00 4.87 3444.98 3450 9.70 
 
 
 
 
 
 
 
 
 
 
Appendix 131 
 
Simulated concentration-time profile of etoposide administered every 12 h 
with 10-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 2520 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 504 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 1608 ng/mL to obtain an etoposide 
concentration of 504 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 503.84 - - 504.00 
0.25 - 0.50 451.35 522.32 522 451.38 
0.50 - 1.00 328.67 1359.32 1350 329.51 
1.00 - 2.00 193.65 2061.50 2050 194.41 
2.00 - 4.00 96.00 2530.94 2550 95.26 
4.00 - 8.00 50.44 2352.80 2350 50.49 
8.00 - 12.00 31.28 1902.26 1900 31.30 
Only for day 6  
0.00 - 12.00 9.74 3444.98 3450 9.70 
 
 
 
 
 
 
 
 
 
 
Appendix 132 
 
Simulated concentration-time profile of etoposide administered every 12 h 
with 5-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 3780 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 756 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 2410 ng/mL to obtain an etoposide 
concentration of 756 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 755.75 - - 756.00 
0.25 - 0.50 677.03 522.32 522 677.07 
0.50 - 1.00 493.00 1359.32 1350 494.26 
1.00 - 2.00 290.48 2061.50 2050 291.62 
2.00 - 4.00 144.00 2530.94 2550 142.89 
4.00 - 8.00 75.65 2352.80 2350 75.73 
8.00 - 12.00 46.92 1902.26 1900 46.95 
Only for day 6  
0.00 - 12.00 14.60 3444.98 3450 14.56 
 
 
 
 
 
 
 
 
 
 
Appendix 133 
 
Simulated concentration-time profile of etoposide administered every 24 h 
with 15-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 2995 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 599 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 1978 ng/mL to obtain an etoposide 
concentration of 599 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 599.21 - - 599.00 
0.25 - 0.50 535.59 529.34 529 535.63 
0.50 - 1.00 386.07 1396.08 1400 385.65 
1.00 - 2.00 219.78 2150.49 2150 219.82 
2.00 - 4.00 99.05 2747.04 2750 98.92 
4.00 - 8.00 45.94 2677.93 2650 46.49 
8.00 - 12.00 27.55 2037.67 2000 27.90 
12.00 - 16.00 18.23 1733.32 1750 18.13 
16.00 - 20.00 12.08 1668.17 1650 12.15 
20.00 - 24.00 8.01 1702.85 1700 8.02 
Only for day 6 
0.00 - 12.00 3.48 2830.30 2850 3.45 
 
 
 
 
 
 
 
Appendix 134 
 
Simulated concentration-time profile of etoposide administered every 24 h 
with 10-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 5990 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 1198 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 3956 ng/mL to obtain an etoposide 
concentration of 1198 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 1198.41 - - 599.00 
0.25 - 0.50 1071.17 529.34 529 535.63 
0.50 - 1.00 772.14 1396.08 1400 385.65 
1.00 - 2.00 439.57 2150.49 2150 219.82 
2.00 - 4.00 198.10 2747.04 2750 98.92 
4.00 - 8.00 91.88 2677.93 2650 46.49 
8.00 - 12.00 55.09 2037.67 2000 27.90 
12.00 - 16.00 36.45 1733.32 1750 18.13 
16.00 - 20.00 24.17 1668.17 1650 12.15 
20.00 - 24.00 16.02 1702.85 1700 8.02 
Only for day 6  
0.00 - 12.00 6.96 2830.30 2850 
 
 
 
 
 
 
 
 
Appendix 135 
 
Simulated concentration-time profile of etoposide administered every 24 h 
with 5-fold dilution of CSF concentrations  
At 0 h of day 1 (day time), 1 mL of etoposide 8990 ng/mL was added to 
4 mL medium to obtain an etoposide concentration of 1798 ng/mL 
At 0 h of day 1 (night time) and day 2 - 5, 1.5 mL of broth solution was 
replaced by 1.5 mL of etoposide 5937 ng/mL to obtain an etoposide 
concentration of 1798 ng/mL 
Time [h] 
Theoretical 
concentration 
[ng/mL] 
Calculated 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Practical 
volume of 
withdrawn / 
replaced 
medium  
[µL] 
Obtained 
concentration 
[ng/mL] 
0.00 - 0.25 1797.62 - - 1798.00 
0.25 - 0.50 1606.76 531.82 532 1606.69 
0.50 - 1.00 1158.21 1395.67 1400 1156.82 
1.00 - 2.00 659.35 2150.16 2150 659.39 
2.00 - 4.00 297.15 2746.78 2750 296.72 
4.00 - 8.00 137.82 2677.67 2650 139.46 
8.00 - 12.00 82.64 2037.33 2000 83.68 
12.00 - 16.00 54.68 1732.94 1750 54.39 
16.00 - 20.00 36.25 1667.79 1650 36.44 
20.00 - 24.00 24.03 1702.48 1700 24.05 
Only for day 6  
0.00 - 12.00 10.44 2830.05 2850 10.34 
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Appendix B4 
Individual data of the colony forming assay 
 (effect of dosage regimen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 137 
 
Number and percent colonies remaining of D-425med incubated with 
simulated CSF concentration-time profiles (every 12 h for five consecutive 
days); results of the respective control experiment are given in brackets) 
 No. of colonies % colonies remaining Mean 
AUC
total 
1 2 3 1 2 3  
5.60 
30 
(41) 
46 
(61) 
70 
(101) 
73.17 75.41 69.31 72.63 
11.20 
49  
(60) 
36  
(63) 
34 
(83) 
81.67 57.14 40.96 59.92 
16.80 
28 
(111) 
66 
(144) 
51 
(133) 
25.23 45.83 38.35 36.47 
 
 
Number and percent colonies remaining of D-425med incubated with 
simulated CSF concentration-time profiles (every 24 h for five consecutive 
days); results of the respective control experiment are given in brackets) 
 No. of colonies % colonies remaining Mean 
AUCtotal 1 2 3 1 2 3  
6.73 
87 
(78) 
106 
(115) 
168 
(166) 
111.54 92.17 101.20 101.64 
13.45 
57 
(82) 
 80 
(135) 
101 
(194) 
69.51 59.26 52.06 60.28 
20.18 
47 
(115) 
34 
(100) 
45 
(108) 
40.87 34.00 41.67 38.85 
 
 
 
 
 
 
